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A B S T R A C T
Background
This is an updated version of the original Cochrane Review published in Issue 2, 2002 and its subsequent updates in 2010 and 2015.
Epilepsy is a common neurological condition in which recurrent, unprovoked seizures are caused by abnormal electrical discharges from
the brain. It is believed that with effective drug treatment, up to 70% of individuals with active epilepsy have the potential to become
seizure-free and go into long-term remission shortly after starting drug therapy with a single antiepileptic drug in monotherapy.
Worldwide, carbamazepine and phenytoin are commonly-used broad spectrum antiepileptic drugs, suitable for most epileptic seizure
types. Carbamazepine is a current first-line treatment for partial onset seizures in theUSA and Europe. Phenytoin is no longer considered
a first-line treatment due to concerns over adverse events associated with its use, but the drug is still commonly used in low- to middle-
income countries because of its low cost. No consistent differences in efficacy have been found between carbamazepine and phenytoin
in individual trials, although the confidence intervals generated by these studies are wide. Differences in efficacy may therefore be shown
by synthesising the data of the individual trials.
Objectives
To review the time to withdrawal, six- and 12-month remission, and first seizure with carbamazepine compared to phenytoin, used as
monotherapy in people with partial onset seizures (simple partial, complex partial, or secondarily generalised tonic-clonic seizures), or
generalised tonic-clonic seizures, with or without other generalised seizure types.
Search methods
For the latest update we searched the Cochrane Epilepsy Group’s Specialised Register (1st November 2016), the Cochrane Central
Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO, 1st November 2016), MEDLINE
(Ovid, 1946 to 1 November 2016), ClinicalTrials.gov (1 November 2016), and theWorld Health Organization (WHO) International
Clinical Trials Registry Platform (ICTRP, 1st November 2016). Previously we also searched SCOPUS (1823 to 16th September 2014)
as an alternative to Embase, but this is no longer necessary, because randomised and quasi-randomised controlled trials in Embase are
now included in CENTRAL. We handsearched relevant journals, contacted pharmaceutical companies, original trial investigators and
experts in the field.
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Selection criteria
Randomised controlled trials (RCTs) in children or adults with partial onset seizures or generalised onset tonic-clonic seizures, comparing
carbamazepine monotherapy versus phenytoin monotherapy.
Data collection and analysis
This is an individual participant data (IPD) review. Our primary outcome was time to withdrawal of allocated treatment, and our
secondary outcomes were time to six-month remission, time to 12-month remission, and time to first seizure post-randomisation.
We used Cox proportional hazards regression models to obtain study-specific estimates of hazard ratios (HRs) with 95% confidence
intervals (CIs) and the generic inverse variance method to obtain the overall pooled HR and 95% CI.
Main results
IPD were available for 595 participants out of 1192 eligible individuals, from four out of 12 trials (i.e. 50% of the potential data).
For remission outcomes, HR greater than 1 indicates an advantage for phenytoin; and for first seizure and withdrawal outcomes, HR
greater than 1 indicates an advantage for carbamazepine. The methodological quality of the four studies providing IPD was generally
good and we rated it at low risk of bias overall in the analyses.
The main overall results (pooled HR adjusted for seizure type) were time to withdrawal of allocated treatment: 1.04 (95% CI 0.78 to
1.39; three trials, 546 participants); time to 12-month remission: 1.01 (95% CI 0.78 to 1.31; three trials, 551 participants); time to
six-month remission: 1.11 (95% CI 0.89 to 1.37; three trials, 551 participants); and time to first seizure: 0.85 (95% CI 0.70 to 1.04;
four trials, 582 participants). The results suggest no overall statistically significant difference between the drugs for these outcomes.
There is some evidence of an advantage for phenytoin for individuals with generalised onset seizures for our primary outcome (time to
withdrawal of allocated treatment): pooled HR 0.42 (95% CI 0.18 to 0.96; two trials, 118 participants); and a statistical interaction
between treatment effect and epilepsy type (partial versus generalised) for this outcome (P = 0.02). However, misclassification of seizure
type for up to 48 individuals (32% of those with generalised epilepsy) may have confounded the results of this review. Despite concerns
over side effects leading to the withdrawal of phenytoin as a first-line treatment in the USA and Europe, we found no evidence that
phenytoin is more likely to be associated with serious side effects than carbamazepine; 26 individuals withdrew from 290 randomised
(9%) to carbamazepine due to adverse effects, compared to 12 out of 299 (4%) randomised to phenytoin from four studies conducted
in the USA and Europe (risk ratio (RR) 1.42, 95% CI 1.13 to 1.80, P = 0.014). We rated the quality of the evidence as low to moderate
according to GRADE criteria, due to imprecision and potential misclassification of seizure type.
Authors’ conclusions
We have not found evidence for a statistically significant difference between carbamazepine and phenytoin for the efficacy outcomes
examined in this review, but CIs are wide and we cannot exclude the possibility of important differences. There is no evidence in this
review that phenytoin is more strongly associated with serious adverse events than carbamazepine. There is some evidence that people
with generalised seizures may be less likely to withdraw early from phenytoin than from carbamazepine, but misclassification of seizure
type may have impacted upon our results. We recommend caution when interpreting the results of this review, and do not recommend
that our results alone should be used in choosing between carbamazepine and phenytoin. We recommend that future trials should be
designed to the highest quality possible, with considerations of allocation concealment and masking, choice of population, choice of
outcomes and analysis, and presentation of results.
P L A I N L A N G U A G E S U M M A R Y
Carbamazepine versus phenytoin (given as a single drug treatment) for epilepsy
Background
Epilepsy is a common neurological disorder in which recurrent seizures are caused by abnormal electrical discharges from the brain.
We studied two types of epileptic seizures in this review: generalised onset seizures in which electrical discharges begin in one part
of the brain and move throughout the brain, and partial onset seizures in which the seizure is generated in and affects only one part
of the brain (the whole hemisphere of the brain or part of a lobe of the brain). For around 70% of people with epilepsy, generalised
onset or partial onset seizures can be controlled by a single antiepileptic drug. Worldwide, phenytoin and carbamazepine are commonly
used antiepileptic drugs, although carbamazepine is used more commonly in the USA and Europe due to concerns over side effects
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associated with phenytoin. Phenytoin is still commonly used in low- and middle-income countries in Africa, Asia and South America,
because of the low cost of the drug.
Objective
For this updated review,we looked at the evidence from12 randomised controlled clinical trials comparing phenytoin and carbamazepine
based on how effective the drugs were at controlling seizures (i.e. whether people went back to having seizures or had long periods of
freedom from seizures (remission)), and how tolerable any related side effects of the drugs were.
Main results
We were able to combine data for 595 people from four of the 12 trials; for the remaining 597 people from eight trials, information
was not available to use in this review. The evidence is current to November 2016.
Results of this review suggest that people with generalised seizures are more likely to withdraw from carbamazepine treatment earlier
than from phenytoin treatment, due to seizure recurrence, side effects of the drug, or both, but for people with partial seizures there
was no difference in times of withdrawal from treatment between the two drugs. Even though phenytoin is thought to cause more and
worse side effects than carbamazepine, we found that twice as many people withdrew from treatment with carbamazepine due to side
effects than from treatment with phenytoin.
Results of the review show no difference between carbamazepine and phenytoin for people achieving long periods of seizure freedom
(six- or 12-month remission of seizures), or experiencing more seizures after starting treatment.
We judge the evidence from this review to be of low to moderate quality. We recommend that caution is used when interpreting the
results of this review, as we were unable to combine the data for all people treated in trials comparing carbamazepine to phenytoin.
Also, up to 30% of people in the trials used in our results may have been wrongly classified as having generalised seizures; this may
have affected the results of our review.
We recommend that any future trials comparing these drugs, or any other antiepileptic drugs, should be designed using high-quality
methods, and that the seizure types of people included in trials should be classified very carefully, to ensure results are of high quality.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Carbamazepine compared with phenytoin for epilepsy
Patient or population: adults and children with new-onset part ial or generalised epilepsy
Settings: outpat ients
Intervention: carbamazepine
Comparison: phenytoin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)1
No. of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Phenytoin Carbamazepine
Time to withdrawal of
allocated treatment
- strat if ied by epilepsy
type
Range of follow-up (all
part icipants): 1 day to
4403 days
37 per 100 35 per 100 (28 to 44) HR 1.04
(0.78 to 1.39)
546
(3 studies)
⊕⊕⊕©
moderate2,3
HR > 1 indicates a clini-
cal advantage for carba-
mazepine
Time to withdrawal of
allocated treatment
- part ial epilepsy
Range of follow-up (all
part icipants): 1 day to
4064 days
42 per 100 37 per 100 (29 to 47) HR 1.18
(0.87 to 1.60)
428
(3 studies)
⊕⊕⊕©
moderate2,3
HR > 1 indicates a clini-
cal
advantage for carba-
mazepine
Time to withdrawal of
allocated treatment
- generalised epilepsy
Range of follow-up (all
part icipants): 1 day to
4403 days
14 per 100 30 per 100 (15 to 57) HR 0.42
(0.18 to 0.96)
118
(2 studies)
⊕⊕⊕©
moderate2,3
HR > 1 indicates a clini-
cal
advantage for carba-
mazepine
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Proport ion of with-
drawals due to adverse
ef fects
Range of follow-up (all
part icipants): 1 day to
4403 days
4 per 100 6 per 100 (5 to 7) RR 1.42
(1.13 to 1.80)
546
(3 studies)
⊕⊕⊕©
moderate2
RR < 1 indicates a clini-
cal
advantage for carba-
mazepine
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The assumed risk is calculated as the event rate in the phenytoin
treatment group. The corresponding risk in the carbamazepine treatment group (and its 95% CI) is based on the assumed risk in the comparison group and the relat ive ef fect
of the intervent ion (and its 95% CI)
The corresponding risk is calculated as the assumed risk x the relat ive risk (RR) of the intervent ion where RR = (1 - exp(HR x ln(1 - assumed risk)) ) / assumed risk
CI: conf idence interval; RR: risk rat io; HR: hazard rat io; exp: exponent ial
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Pooled HR for all part icipants adjusted for seizure type.
2Risk of bias unclear for one element of all of the three studies included in the analysis. De Silva 1996 and Heller 1995 are
open-label and it is unclear whether the lack of masking impacted upon the results; and we do not know how allocat ion was
concealed in Mattson 1985.
329 adult part icipants in Heller 1995 may have had their seizure type wrongly classif ied as generalised onset; sensit ivity
analyses show misclassif icat ion may have had an impact on results and conclusions regarding an associat ion between
treatment and seizure type.
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B A C K G R O U N D
This review is an update of a previously published review in the
Cochrane Database of Systematic Reviews (see Other published
versions of this review).
Description of the condition
Epilepsy is a common neurological condition in which recur-
rent, unprovoked seizures are caused by abnormal electrical dis-
charges from the brain. Epilepsy is a disorder of many hetero-
geneous seizure types, with an estimated incidence of 33 to 57
per 100,000 person-years worldwide (Annegers 1999; Hirtz 2007;
MacDonald 2000; Olaffsson 2005; Sander 1996), accounting for
approximately 1% of the global burden of disease (Murray 1994).
The lifetime risk of epilepsy onset is estimated to be 1300 to
4000 per 100,000 person-years (Hauser 1993; Juul-Jenson 1983),
and the lifetime prevalence could be as large as 70 million people
worldwide (Ngugi 2010). It is believed that with effective drug
treatment, up to 70% of individuals with active epilepsy have the
potential to become seizure-free and go into long-term remission
shortly after starting drug therapy (Cockerell 1995; Hauser 1993;
Sander 2004), and that around 70% of individuals can achieve
seizure freedom using a single antiepileptic drug in monotherapy
(Cockerell 1995); current National Institute for Health and Clini-
cal Excellence (NICE) guidelines recommend that both adults and
children with epilepsy should be treated by monotherapy wher-
ever possible (NICE 2012). The remaining 30% of individuals
experience refractory or drug-resistant seizures which often require
treatment with combinations of antiepileptic drugs, or alternative
treatments such as epilepsy surgery (Kwan 2000).
We study two seizure types in this review: generalised onset seizures
(generalised tonic-clonic seizureswith orwithout other generalised
seizure types), inwhich electrical discharges begin in one part of the
brain and move throughout the brain; and partial onset seizures,
in which the seizure is generated in and affects only one part of
the brain (the whole hemisphere of the brain or part of a lobe of
the brain).
Description of the intervention
Carbamazepine and phenytoin are among the most commonly
used and earliest drugs licensed for the treatment of epileptic
seizures; phenytoin has been used as monotherapy for partial
seizures and generalised tonic-clonic seizures for over 50 years
(Gruber 1962) and carbamazepine for over 30 years (Shakir 1980).
Current NICE guidelines (NICE 2012) for adults and children
recommend carbamazepine as a first-line treatment for partial on-
set seizures and as a second-line treatment for generalised tonic-
clonic seizures if first-line treatments sodium valproate and lamot-
rigine are deemed unsuitable; however, there is evidence that car-
bamazepine may exacerbate some other generalised seizure types
such as myoclonic and absence seizures (Liporace 1994; Shields
1983; Snead 1985). Phenytoin is no longer considered a first-
line treatment in the USA and most of Europe, due to concerns
over adverse events (Wallace 1997; Wilder 1995), but phenytoin
is still used as a first-line drug in low- to middle-income countries
(Ogunrin 2005; Pal 1998).
Both carbamazepine and phenytoin have been shown to have ter-
atogenic effects where the risk is estimated to be two to three times
that of the general population (Gladstone 1992; Meador 2008;
Morrow 2006; Nulman 1997). Carbamazepine is associated par-
ticularly with neural tube defects (Matlow 2012) and phenytoin
is associated with fetal hydantoin syndrome (Scheinfeld 2003),
low folic acid levels and megaloblastic anaemia (Carl 1992). Both
carbamazepine and phenytoin are associated with an allergic rash
(Tennis 1997) in 5% to 10% of users, which on rare occasions may
be life-threatening, and phenytoin is also associated with long-
term cosmetic changes including gum hyperplasia, acne and coars-
ening of the facial features (Mattson 1985; Scheinfeld 2003).
How the intervention might work
Antiepileptic drugs suppress seizures by reducing neuronal ex-
citability. Phenytoin and carbamazepine are broad-spectrum treat-
ments suitable for many seizure types and both have an anticon-
vulsant mechanism through blocking ion channels, binding with
neurotransmitter receptors or through inhibiting the metabolism
or reuptake of neurotransmitters (Ragsdale 1991; Willow 1985)
and the modulation of gamma-aminobutyric acid-A (GABA-A)
receptors (Granger 1995).
Why it is important to do this review
The aim of this review is to summarise efficacy and tolerability
data from existing trials comparing carbamazepine and phenytoin
when used as monotherapy treatments. The adverse event profiles
of the two drugs are well documented (see example references from
Description of the intervention), but no consistent differences in
efficacy have been found between the two drugs from a number of
randomised controlled trials (RCTs) individually (for example:De
Silva 1996; Heller 1995;Mattson 1985; Ramsay 1983). Although
no clear difference in efficacy has been found from individual
studies, the confidence intervals generated by these studies are
wide. We cannot exclude important differences in efficacy, which
may be shown by synthesising the data of the individual trials.
There are difficulties in undertaking a systematic review of epilepsy
monotherapy trials, as the important efficacy outcomes require
analysis of time-to-event data (for example, time to first seizure
after randomisation). Although methods have been developed to
synthesise time-to-event data using summary information (Parmar
1998; Williamson 2002), the appropriate statistics are not com-
monly reported in published epilepsy trials (Nolan 2013a). Fur-
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thermore, although seizure data have been collected in most
epilepsy monotherapy trials, there has been no uniformity in the
definition and reporting of outcomes. For example, trials may re-
port time to 12-month remission but not time to first seizure or
vice versa, or some trials may define time to first seizure from the
date of randomisation, while others use date of achieving a main-
tenance dose. Trial investigators have also adopted differing ap-
proaches to the analysis, particularly with respect to the censoring
of time-to-event data. For these reasons, we performed this review
using individual participant data (IPD), which helps to overcome
these problems. This review is one in a series of Cochrane IPD
Reviews investigating pair-wise monotherapy comparisons. These
data have also been included in a network meta-analysis (Tudur
Smith 2007), undertaken following a previous version of this re-
view.
O B J E C T I V E S
To review the time to withdrawal, six- and 12-month remis-
sion, and first seizure with carbamazepine compared to pheny-
toin, used as monotherapy in people with partial onset seizures
(simple partial, complex partial, or secondarily generalised tonic-
clonic seizures) or generalised tonic-clonic seizures, with or with-
out other generalised seizure types.
M E T H O D S
Criteria for considering studies for this review
Types of studies
1. Studies must be randomised controlled trials (RCTs) using
either an adequate method of allocation concealment (e.g. sealed
opaque envelopes) or a quasi-randomised method of allocation
(e.g. allocation by date of birth).
2. Studies must be of parallel design; cross-over studies are not
an appropriate design for measuring the long-term outcomes of
interest in this review (see Types of outcome measures).
3. Studies must include a comparison of carbamazepine
monotherapy with phenytoin monotherapy in individuals with
epilepsy; cluster-randomised studies are therefore not an eligible
design.
We included studies regardless of blinding method (unblinded,
single-blind or double-blind).
Types of participants
1. We included trials recruiting children or adults with partial
onset seizures (simple partial, complex partial, or secondarily
generalised tonic-clonic seizures) or generalised onset tonic-
clonic seizures (as a primary generalised seizure type), with or
without other generalised seizure types (e.g. absence, myoclonic,
etc.).
2. We excluded studies that recruited only individuals with
other generalised seizure types, without generalised tonic-clonic
seizures (such as studies recruiting only individuals with a
diagnosis of absence seizures or juvenile myoclonic epilepsy, etc.)
due to differences in first-line treatment guidelines (NICE 2012).
3. We included individuals who had a new diagnosis of
epilepsy or who had experienced a relapse following antiepileptic
monotherapy withdrawal only, due to differences in first-line
treatment guidelines for individuals with refractory epilepsy
(NICE 2012).
Types of interventions
Carbamazepine versus phenytoin (any doses) as monotherapy.
Types of outcome measures
We present the outcomes investigated in this review. Reporting of
these outcomes in the original trial report was not an eligibility
requirement for this review:
Primary outcomes
1. Time to withdrawal of allocated treatment (retention time)
is the primary outcome. This is a combined outcome, reflecting
both efficacy and tolerability, as treatment may be withdrawn
due to continued seizures, side effects, non-compliance or if
additional add-on treatment was initiated (i.e. allocated
treatment had failed). This is an outcome to which the
participant makes a contribution, and is the primary outcome
measure recommended by the Commission on Antiepileptic
Drugs of the International League Against Epilepsy
(Commission 1998; ILAE 2006).
Secondary outcomes
1. Time to achieve 12-month remission (seizure-free period).
2. Time to achieve six-month remission (seizure-free period).
3. Time to first seizure post-randomisation.
4. Adverse events (including those relating to treatment
withdrawal)
Search methods for identification of studies
Electronic searches
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We conducted searches for the original review in 1999, and subse-
quently in 2001, 2003, 2005, July 2007,November 2009,Novem-
ber 2011, October 2013, and September 2014. For the latest up-
date we searched the following databases, applying no language
restrictions:
• The Cochrane Epilepsy Group’s Specialized Register (1st
November 2016), using the search strategy outlined in Appendix
1.
• The Cochrane Central Register of Controlled Trials
(CENTRAL) via the Cochrane Register of Studies Online
(CRSO, 1st November 2016), using the search strategy outlined
in Appendix 2.
• MEDLINE (Ovid, 1946 to 1st November 2016), using the
search strategy outlined in Appendix 3.
• ClinicalTrials.gov (1st November 2016), using the search
terms ’carbamazepine and phenytoin and epilepsy | Studies
received on or after 09/16/2014’.
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP, 1st November 2016), using the
search terms ’carbamazepine and phenytoin and epilepsy not
NCT*’ (new items selected manually).
Previously we also searched SCOPUS (1823 to 16th September
2014), using the search strategy outlined in Appendix 4, as an
alternative to Embase, but this is no longer necessary, because
randomised and quasi-randomised controlled trials in Embase are
now included in CENTRAL.
Searching other resources
In addition, we handsearched relevant journals, reviewed the ref-
erence lists of retrieved studies to search for additional reports
of relevant studies, contacted Novartis (manufacturers of carba-
mazepine), Parke-Davis (manufacturers of phenytoin), and experts
in the field for information on any ongoing studies, and original
investigators of relevant trials found.
Data collection and analysis
Selection of studies
Two review authors (SJN and AGM) independently assessed trials
for inclusion, resolving any disagreements by discussion.
Data extraction and management
We requested the following individual participant data (IPD) for
all trials meeting our inclusion criteria:
Trial methods:
• method of generation of random list
• method of concealment of randomisation
• stratification factors
• blinding methods
Participant covariates:
• gender
• age
• seizure types
• time between first seizure and randomisation
• number of seizures prior to randomisation (with dates)
• presence of neurological signs
• electroencephalographic (EEG) results
• computerised tomography/magnetic resonance imaging
(CT/MRI) results
Follow-up data:
• treatment allocation
• date of randomisation
• dates of follow-up
• dates of seizures post-randomisation or seizure frequency
data between follow-up visits
• dates of treatment withdrawal and reasons for treatment
withdrawal
• dose
• dates of dose changes
For each trial for which we did not obtain IPD, we carried out
an assessment to see whether any relevant aggregate-level data had
been reported.
In one study (Mattson 1985), seizure data were provided in terms
of the number of seizures recorded between each follow-up visit
rather than specific dates of seizures. To enable us to calculate
time-to-event outcomes, we applied linear interpolation to ap-
proximate dates of seizures between follow-up visits, assuming a
uniform seizure rate. For example, if four seizures were recorded
between two visits which occurred on 1st March 1990 and 1st
May 1990 (an interval of 61 days), then the date of first seizure
would be approximately 13th March 1990 (i.e. 61 days divided by
number of seizures plus 1 rounded to the next day, i.e. 13 days).
This allowed us to compute an estimate of the time to six-month
remission, 12-month remission, and the time to first seizure.
We calculated time to six-month and 12-month remission from
the date of randomisation to the date (or estimated date) the in-
dividual had first been free of seizures for six or 12 months re-
spectively. If the person had one or more seizures in the titration
period, a six-month or 12-month seizure-free period could also
occur between the estimated date of the last seizure in the titration
period and the estimated date of the first seizure in the mainte-
nance period.
We calculated time to first seizure from the date of randomisation
to the date that their first seizure was estimated to have occurred.
If seizure data were missing for a particular visit, we censored these
outcomes at the previous visit. We also censored these outcomes if
the individual died or if follow-up ceased prior to the occurrence
of the event of interest. These methods had been used in the
remaining three trials (De Silva 1996;Heller1995;Ogunrin 2005)
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for which outcome data (dates of seizures after randomisation)
were provided directly.
In one trial (Ogunrin 2005), all participants completed the 12-
week trial duration without withdrawing from the study. For three
trials (De Silva 1996; Heller 1995; Mattson 1985) we extracted
dates and reason for treatment withdrawal from trial case report
forms for the original review. Two review authors (SJN and CT)
independently extracted data from all case report forms, resolving
disagreements by reconsidering the case report forms at confer-
ence. For the remaining trials, data on length of time spent in trial
and reason for withdrawal of allocated treatment were provided
directly. For the analysis of time to event, we defined an ’event’
as either the withdrawal of the allocated treatment due to poor
seizure control, or adverse events, or both. We also classified non-
compliance with the treatment regimen or the addition of another
antiepileptic drug as ’events’. We censored the outcome if treat-
ment was withdrawn because the individual achieved a period of
remission, or if the individual was still on allocated treatment at
the end of follow-up.
Assessment of risk of bias in included studies
Two review authors (SJN and JW) independently assessed all in-
cluded studies for risks of bias (Higgins 2011), resolving any dis-
agreements by discussion. The domains assessed as being at low,
high or unclear risk of bias were random sequence generation,
allocation concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome data, selec-
tive reporting, and other potential sources of bias. We took into
account all available information for an included study whenmak-
ing risk of bias judgements, including multiple publications of the
study and additional information provided from study authors
with IPD.
Measures of treatment effect
We measured all outcomes in this review as time-to-event out-
comes with the hazard ratio (HR). We calculated outcomes from
IPD provided where possible or extracted summary statistics from
published studies.
Unit of analysis issues
We did not have any unit of analysis issues. The unit of allocation
and analysis was the individual participant for all included studies
and no studies were of a repeated measure, (longitudinal) nature,
or of a cross-over design.
Dealing with missing data
For each trial where IPD were supplied, we reproduced informa-
tion from trial results where possible, and performed the following
consistency checks:
• We cross-checked trial details against any published report
of the trial and contacted original trial authors if we found
missing data, errors or inconsistencies.
• We reviewed the chronological randomisation sequence,
and checked the balance of participant characteristics, taking
account of factors stratified for in the randomisation procedure.
Assessment of heterogeneity
We assessed heterogeneity statistically using the Q test (P value <
0.10 for significance) and the I2 statistic (Higgins 2003) (greater
than 50% indicating considerable heterogeneity), output pro-
duced using the generic inverse variance approach in Metaview,
and visually by inspecting forest plots.
Assessment of reporting biases
Two review authors (SJN and JP) undertook all full quality and risk
of bias assessments. In theory, a review using IPD should overcome
issues of reporting biases, as unpublished data can be provided
and unpublished outcomes calculated. Any selective reporting bias
detected could be assessed with the ORBIT classification system
(Kirkham 2010).
Data synthesis
We carried out our analysis on an intention-to-treat basis (that
is, analysing participants in the group to which they were ran-
domised, irrespective of which treatment they actually received).
For the time-to-event outcomes ’Time to six-month remission’,
’Time to 12-month remission’ and ’Time to first seizure post-ran-
domisation’, participants were therefore not censored if the treat-
ment initially assigned was withdrawn.
For all outcomes, we investigated the relationship between the
time-to-event and treatment effect of the antiepileptic drugs. We
used Cox proportional hazards regression models to obtain study-
specific estimates of log (HR) or treatment effect and associated
standard errors in statistical software SAS version 9.2 (Copyright,
SAS Institute Inc. SAS and all other SAS Institute Inc. product
or service names are registered trademarks or trademarks of SAS
Institute Inc., Cary, NC, USA.). The model assumes that the ratio
of hazards (risks) between the two treatment groups is constant
over time (i.e. hazards are proportional). We tested this propor-
tional hazards assumption of the Cox regression model for each
outcome of each study by testing the statistical significance of a
time-varying covariate in the model. We also inspected Kaplan-
Meier plots for overlapping of curves, which can indicate depar-
tures from proportional hazards. We evaluated overall estimates
of HRs (with 95% confidence intervals (CIs)) using the generic
inverse variance method. We expressed results as a hazard ratio
(HR) with 95% CIs.
By convention, a HR greater than 1 indicates that an event is more
likely to occur earlier with carbamazepine than with phenytoin.
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Hence, for time to withdrawal of allocated treatment or time to
first seizure, a HR greater than 1 indicates a clinical advantage for
phenytoin (e.g. HR = 1.2 would suggest a 20% increase in the risk
of withdrawal from carbamazepine compared to phenytoin) and
for time to six-month and 12-month remission a HR greater than
1 indicates a clinical advantage for carbamazepine.
We used GRADE (GRADE 2004) quality assessment criteria in
the ’Summary of findings’ tables.
Subgroup analysis and investigation of heterogeneity
Due to the strong clinical belief that some antiepileptic drugs are
more effective in some seizure types than others (see Description
of the intervention and How the intervention might work), we
have stratified all analyses by seizure type (partial onset versus
generalised onset), according to the classification of main seizure
type at baseline. We classified partial seizures (simple or complex)
and partial secondarily generalised seizures as partial epilepsy. We
classified primarily generalised seizures as generalised epilepsy. To
statistically assess an association between treatment and seizure
type we conducted a Chi2 test of interaction between treatment
and epilepsy type.
If we found significant statistical heterogeneity to be present, we
performed meta-analysis with a random-effects model in addition
to a fixed-effect model, presenting the results of both models and
performing sensitivity analyses to investigate differences in study
characteristics.
Sensitivity analysis
Misclassificationof seizure type is a recognised problem in epilepsy,
whereby some people with generalised seizures have been mistak-
enly classed as having partial onset seizures, and vice versa. There
is clinical evidence that individuals with generalised onset seizures
are unlikely to have an ’age of onset’ greater than 25 to 30 years
(Malafosse 1994). In a previous review, in our series of pair-wise
reviews for monotherapy in epilepsy, misclassification impacted
upon the results (Nolan 2013b). Given the overlap with studies
contributing to this review and the phenytoin versus sodium val-
proate review (Nolan 2013b), we suspected that misclassification
of seizure type could also be likely in this review, and so we ex-
amined the distribution of age at onset for individuals with gen-
eralised seizures.
De Silva 1996 was a paediatric study and Mattson 1985 recruited
participants with partial seizures only, so there were no participants
with new-onset generalised seizures over the age of 30 in these
studies. Twenty-nine out of 72 individuals (42%) with generalised
onset seizures were over the age of 30 in Heller 1995, and 19 out
of 29 individuals (66%) with generalised onset seizures were over
the age of 30 in Ogunrin 2005. Therefore out of 150 participants
from the four studies providing IPD, 48 (32%) may have been
wrongly classified as having new-onset generalised seizures.
We undertook the following two sensitivity analyses to investigate
misclassification for each outcome:
1. We reclassified the 48 individuals with generalised seizure
types and age at onset greater than 30 into an ’uncertain seizure
type’ group.
2. We reclassified the 48 individuals with generalised seizures
and age of onset greater than 30 as having partial seizures.
R E S U L T S
Description of studies
Results of the search
We identified 655 records from the databases and search strategies
outlined in Electronic searches. We found three further records
by handsearching and checking reference lists of included studies.
We removed 265 duplicate records and screened 393 records (title
and abstract) for inclusion in the review. We excluded 354 records
based on title and abstract and assessed 39 full-text articles for
inclusion in the review. We excluded 14 studies (reported in 20
full-text articles) from the review (see Excluded studies below) and
included 12 trials (reported in 18 full-text articles) in the review
(see Included studies below). One study is awaiting classification
following translation (Rysz 1994). See Figure 1 for PRISMA study
flow diagram (Moher 2009).
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Figure 1. Study flow diagram.
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Included studies
We included 12 trials in this review (Callaghan 1985; Cereghino
1974; Czapinski 1997; De Silva 1996; Forsythe 1991; Heller
1995; Mattson 1985; Miura 1993; Ogunrin 2005; Pulliainen
1994; Ramsay 1983; Ravi Sudhir 1995). One trial was available
in abstract form only (Czapinski 1997).
One trial recruited individuals of all ages (Callaghan 1985), three
trials recruited children only (defined as under the age of 16 in De
Silva 1996, and under the age of 14 in Forsythe 1991 and Miura
1993); and the remaining eight trials recruited adults only. Four
trials defined adults as individuals above the age of 18 (Cereghino
1974; Czapinski 1997; Mattson 1985; Ramsay 1983), one trial
classed adults as older than13years (Heller 1995), two trials classed
adults as older than 14 years (Ogunrin 2005; Ravi Sudhir 1995)
and one trials classed adults as older than 15 years (Pulliainen
1994).
Ten trials recruited individuals with partial onset seizures and
generalised onset seizures (Callaghan 1985; Cereghino 1974; De
Silva 1996; Forsythe 1991; Heller 1995; Miura 1993; Ogunrin
2005; Pulliainen 1994; Ramsay 1983; Ravi Sudhir 1995), and
two trials recruited individuals with partial onset seizures only
(Czapinski 1997; Mattson 1985). Ten trials recruited individu-
als with new-onset seizures or previously untreated seizures, or
both (Callaghan 1985; Czapinski 1997; De Silva 1996; Forsythe
1991; Heller 1995; Miura 1993; Ogunrin 2005; Pulliainen 1994;
Ramsay 1983; Ravi Sudhir 1995). One trial recruited institution-
alised participants with uncontrolled seizures (Cereghino 1974),
and one trial recruited “previously untreated or under treated” in-
dividuals (Mattson 1985).
Six trials were conducted in Europe (Callaghan 1985; Czapinski
1997; De Silva 1996; Forsythe 1991; Heller 1995; Pulliainen
1994), three in theUSA (Cereghino 1974;Mattson 1985; Ramsay
1983), one in Nigeria (Ogunrin 2005), one in India (Ravi Sudhir
1995), and one in Japan (Miura 1993).
Individual participant data (IPD) could not be supplied for eight
trials (Callaghan 1985;Cereghino1974;Czapinski 1997; Forsythe
1991; Miura 1993; Pulliainen 1994; Ramsay 1983; Ravi Sudhir
1995), in which 597 individuals had been randomised to either
phenytoin or carbamazepine. None of these eight trials reported
the specific time-to-event outcomes chosen for this systematic re-
view.
Forsythe 1991 presented times at which the allocated drug was
withdrawn and the reason for withdrawal in the trial publication
for each individual. Hence, we were able to incorporate this trial
into the analysis of ’Time towithdrawal of allocated treatment’. For
each participant, ’withdrawal and time of occurrence by month’
was presented and therefore to calculate ’Time to withdrawal of
allocated treatment’ we assumed that, for example, if withdrawal
occurred during the fifthmonth, thatwithdrawal occurred halfway
between the fifth and sixth month (i.e. participants spent 167 full
days on treatment before withdrawal).
We could not extract sufficient aggregate data from the trial publi-
cation in any other trial, and we therefore could not include them
in data synthesis. Full details of outcomes considered and a sum-
mary of results in each eligible trial for which IPD were not avail-
able can be found in Table 1.
IPD were provided by trial authors for the four remaining trials
which recruited 595 participants, representing 49.9% of individ-
uals from 1192 individuals in all eligible trials (De Silva 1996;
Heller 1995; Mattson 1985; Ogunrin 2005). Two trials (Mattson
1985; Ogunrin 2005) directly provided computerised data, and
the authors of the other two trials (Heller 1995; De Silva 1996)
supplied a combination of both computerised and paper-based
(although mostly computerised) data.
Data were available for the following subject characteristics (per-
centage of 595 participants with data available): sex (100%),
seizure type (100%), drug randomised (99% - data missing for six
participants in De Silva 1996), sex (99% - data missing for eight
participants), age at randomisation (98% - data missing for nine
participants), number of seizures in six months prior to randomi-
sation (98% - data missing for 11 participants), time since first
seizure to randomisation (98% - data missing for 10 participants).
The results of neurological examinations were provided for 326
participants (55%) from three trials (De Silva 1996; Heller 1995;
Ogunrin 2005), electroencephalographic (EEG) results were pro-
vided for 316 participants (53%) from one trial (Mattson 1985)
and computerised tomography/magnetic resonance imaging (CT/
MRI) results were provided for 324 participants (54%) in two
trials (Mattson 1985; Ogunrin 2005).
Excluded studies
We excluded five studies which were not RCTs (Bird 1966;
Kuzuya 1993; Sabers 1995; Shorvon 1978; Zeng 2010). We ex-
cluded seven trials which did not use carbamazepine and pheny-
toin in monotherapy (Bittencourt 1993; Canadian Study 1998;
Hakami 2012; Kosteljanetz 1979; Rajotte 1967; Simonsen 1976;
Troupin 1975), and we excluded two trials which did not make
a randomised comparison between carbamazepine and phenytoin
monotherapy (Kaminow 2003; Shakir 1980). See Characteristics
of excluded studies for further details.
Risk of bias in included studies
For further details see Characteristics of included studies, Figure
2 and Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
(1) Trials for which individual participant data (IPD) were
provided
Three trials reported adequate methods of randomisation and al-
location concealment; two trials used permuted blocks to generate
a random list and concealed allocation by using sealed opaque en-
velopes (De Silva 1996; Heller 1995), and one trial used number
tables to generate a random list and concealed allocation by allo-
cating the randomised drug on a different site from where partic-
ipants were randomised (Ogunrin 2005). One trial reported only
that participants were randomised with stratification for seizure
type (Mattson 1985); no further information was provided in the
study publication or from the authors about the methods of gen-
erating the random list and concealment of allocation.
(2) Trials for which no IPD were available
One trial reported an adequate method of randomisation: ran-
dom-number tables (Cereghino 1974), but no details were pro-
vided on concealment of allocation.Two trials reported inadequate
methods of randomisation and allocation concealment; Forsythe
1991 reported a method of quota allocation and did not report
how allocation was concealed, and Callaghan 1985 reported a
method of randomisation and allocation concealment based on
two Latin squares which seems to take into account the drug pref-
erence of participants (the “drug of first preference” was selected
from the randomisation list on a sequential basis). The remaining
five trials (Czapinski 1997; Miura 1993; Pulliainen 1994; Ramsay
1983; Ravi Sudhir 1995) reported that the participants were “ran-
domised” or “randomly allocated” etc., but did not provide in-
formation of the method of generation of the random list or of
allocation concealment.
Blinding
(1) Trials for which IPD were provided
One trial double-blinded participants and personnel using an ad-
ditional blank tablet (Mattson 1985), but it is unclear if the out-
come assessor was blinded in this trial. One trial blinded partic-
ipants and the outcome assessors who performed cognitive test-
ing, but a research assistant recruiting participants and providing
counselling on medication adherence was not blinded (Ogunrin
2005). Two trials were unblinded for “practical and ethical rea-
sons” (De Silva 1996; Heller 1995), but it is unclear whether the
outcomes of these trials were influenced by the lack of masking.
(2) Trials for which no IPD were available
One trial double-blinded participants and personnel using an ad-
ditional blank tablet (Ramsay 1983), but it is unclear if the out-
come assessor was blinded in this trial. Two trials single-blinded
the outcome assessor who performed cognitive testing; in one of
these trials (Forsythe 1991) the participants and personnel were
unblinded, and in the other (Pulliainen 1994), it was unclear if
the participants and personnel were blinded or not. The remain-
ing five trials (Callaghan 1985; Cereghino 1974; Czapinski 1997;
Miura 1993; Ravi Sudhir 1995) did not provide any information
on masking of participants, personnel or outcome assessors.
Incomplete outcome data
(1) Trials for which IPD were provided
In theory, a review using IPD should overcome issues of attri-
tion bias, as unpublished data can be provided, unpublished out-
comes calculated and all randomised participants can be analysed
by an intention-to-treat approach. All four trials (De Silva 1996;
Heller 1995; Mattson 1985; Ogunrin 2005) provided IPD for all
randomised individuals and reported the extent of follow-up for
each individual. We queried any missing data with the original
study authors. From the information provided by the authors, we
deemed the small amount of missing data (Included studies) to
be missing at random and that they did not have an effect on our
analysis.
(2) Trials for which no IPD were available
Three trials reported attrition rates and analysed all randomised
participants using an intention-to-treat approach (Callaghan
1985; Forsythe 1991; Miura 1993). Two trials reported attrition
rates, but it was unclear if all participants were analysed (Cereghino
1974; Czapinski 1997). Three studies excluded between 20% and
35% of participants from the final analysis for “non-compliance,”
loss to follow-up or uncontrolled seizures, and included only those
who completed the analysis. This approach is not intention-to-
treat, so we deemed these three studies to be at high risk of bias
(Pulliainen 1994; Ramsay 1983; Ravi Sudhir 1995)
Selective reporting
We requested study protocols in all IPD requests, but protocols
were not available for any of the 12 included trials, so we made a
judgement of the risk of bias based on the information included in
the publications, or from the IPD we received (see Characteristics
of included studies for more information).
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Trials for which IPD were provided
In theory, a review using IPD should overcome issues of reporting
biases, as unpublished data can be provided and unpublished out-
comes calculated. We acquired sufficient IPD to calculate the four
outcomes (’Time to withdrawal of allocated treatment’, ’Time to
six-month remission’,’Time to 12-month remission’ and ’Time to
first seizure’) for three of the four trials (De Silva 1996; Heller
1995; Mattson 1985). The study duration of Ogunrin 2005 was
12 weeks and all randomised participants completed the study
without withdrawing, so we could only calculate ’Time to first
seizure’ for this study.
Trials for which no IPD were available
Seizure outcomes or adverse events, or both, were fully reported
in four trials (Callaghan 1985; Cereghino 1974; Miura 1993;
Ramsay 1983). Two trials reported cognitive outcomes and adverse
events, but no seizure outcomes (Forsythe 1991; Pulliainen 1994),
and one trial reported cognitive outcomes only, but no adverse
events or seizure outcomes (Ravi Sudhir 1995); however, as no
protocols were available for these three trials, we do not know
whether seizure outcomes or recording of adverse events, or both,
were planned a priori. One trial was in abstract form only and did
not provide sufficient information to assess selective reporting bias
(Czapinski 1997).
Other potential sources of bias
We detected another source of bias in one of the included studies
which has a cross-over design (Cereghino 1974). Such a design
is unlikely to be appropriate for monotherapy treatment, due to
carry-over effects from one treatment period into another (partici-
pants were also treated during washout periods with their “regular
medication”), and such a design does not allow long-term out-
comes such as the time-to-event outcomes of interest to us in this
review. For future updates of this review we will exclude studies of
a cross-over design.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings - Time to withdrawal of allocated treatment; Summary
of findings 2 Summary of findings - Time to 12- and 6-month
remission of seizures; Summary of findings 3 Summary of
findings - Time to first seizure after randomisation
A summary of the outcomes reported in trials for which no IPD
were available are reported in Table 1. Details regarding the num-
ber of individuals (with IPD) contributing to each analysis are
given inTable 2 and results are summarised in Summary of findings
for the main comparison for our primary outcome ’Time to with-
drawal of allocated treatment’, Summary of findings 2 for the
secondary outcomes ’Time to six- and 12-month remission’ and
Summary of findings 3 for the secondary outcome ’Time to first
seizure’. Survival curve plots (cumulative incidence) are shown in
Figure 4; Figure 5; Figure 6; Figure 7; Figure 8; Figure 9; Figure
10 and Figure 11. We produced all cumulative incidence plots in
Stata software version 11.2 (Stata 2009), using data from all trials
providing IPD combined. We would have liked to adjust for in-
dividual trials in survival curve plots but we do not know of any
software which allows for this; we hope that such software may
have been developed for future updates of this review.
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Figure 4. Time to withdrawal of allocated treatment
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Figure 5. Time to withdrawal of allocated treatment, stratified by epilepsy type
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Figure 6. Time to 12 month remission
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Figure 7. Time to 12 month remission, stratified by epilepsy type
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Figure 8. Time to 6 month remission
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Figure 9. Time to 6 month remission, stratified by epilepsy type
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Figure 10. Time to first seizure
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Figure 11. Time to first seizure, stratified by epilepsy type
All hazard ratios (HRs) presented below are calculated by generic
inverse variance fixed-effect meta-analysis unless otherwise stated.
Time to withdrawal of allocated treatment
For this outcome, a HR greater than one indicates a clinical ad-
vantage for carbamazepine.
Time to withdrawal of allocated treatment and reason for with-
drawal were available for 546 participants from three of the four
trials providing IPD (99%of 558 participants fromDe Silva 1996,
Heller 1995 andMattson 1985 (see Included studies), and 45.8%
of the 1192 participants from the 12 included studies). Although
two participants withdrew from allocated treatment (one in each
group) in De Silva 1996, a reason for withdrawal was not available
and could not be determined from the case notes. Similarly in
Heller 1995, for one participant taking carbamazepine, the rea-
son for withdrawal was not available and could not be determined
from case notes. Also in Heller 1995, two participants (both on
phenytoin) had reasons for treatment withdrawal recorded but no
date of withdrawal. We have not included the five participants
with missing reasons for withdrawal or withdrawal dates from the
two trials in analysis of time to withdrawal of allocated treatment.
Sufficient IPD were available in the published report for a further
43 participants from one trial (Forsythe 1991). Therefore, 589
participants from four trials were available for the analysis of this
outcome (see Table 2).
350 participants prematurely withdrew from treatment (59%):
172 out of 290 participants randomised to carbamazepine (59%)
and 178 out of 299 participants randomised to phenytoin (60%).
See Table 3 for reasons for premature termination of allocated
treatment (by treatment) and how we classified these withdrawals
in analysis.We deemed 210 participants (36%) to have withdrawn
for reasons related to the study drug, 103 (36%) on carbamazepine
and 107 (36%) on phenytoin, and we classified these withdrawals
as ’events’ in analysis. We classified the other 140 withdrawals as
not related to the study drug and censored these participants in
analysis, in addition to those who completed the study without
withdrawing.
The overall pooledHR(for 589participants in four trials) was 0.99
(95% confidence interval (CI) 0.75 to 1.30, P = 0.92), indicating
no advantage for either drug. There was no evidence of statistical
heterogeneity between trials (Chi2 = 2.73, degrees of freedom (df )
= 3, P = 0.44, I2= 0%, see Analysis 1.1). The proportional hazards
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assumption of the Cox model was satisfied for all trials.
Phenytoin is no longer considered as a first-line treatment inmuch
of theUSA andEurope, due to concerns around adverse events (see
Description of the intervention). Table 3 shows that 26 out of 172
participants (15%) who withdrew from carbamazepine and 12 out
of 178 participants (7%) who withdrew from phenytoin withdrew
from the study due to adverse events; in other words, statistically
significantlymore participantswithdrew fromcarbamazepine than
from phenytoin due to adverse events in four studies conducted
in the USA and Europe ( P = 0.012).
Withdrawal data for 43 participants extracted from Forsythe 1991
did not distinguish between epilepsy type (partial onset or gen-
eralised onset) and therefore could not be included in the meta-
analysis stratified by epilepsy type.
The overall pooled HR (adjusted by epilepsy type for 546 partic-
ipants in three trials) was 1.04 (95% CI 0.78 to 1.39, P = 0.79),
again indicating no clear advantage for either drug, and there was
no evidence of statistical heterogeneity between trials (Chi2 = 5.86,
df = 4, P = 0.21, I2= 32%, see Analysis 1.2). This result is similar to
the unadjusted pooled HR (Analysis 1.1) and conclusions remain
unchanged following the exclusion of 43 individuals (Forsythe
1991) in the stratified analysis.
For participants with partial onset seizures (n = 428, three tri-
als), the pooled HR was 1.18 (95% CI 0.87 to 1.60, P = 0.30),
indicating an advantage for carbamazepine, which is not statisti-
cally significant. For participants with generalised onset seizures
(n = 118, two trials), the pooled HR was 0.42 (95% CI 0.18 to
0.96, P = 0.04), indicating a statistically significant advantage for
phenytoin.We found a statistically significant interaction between
seizure type (generalised versus partial onset) and treatment effect
(Chi2 = 5.18, df = 1, P = 0.02, I2= 80.7%).
We conducted a sensitivity analysis to examine the impact of po-
tential seizure misclassification on results for the 29 participants
aged 30 years or older with new-onset generalised seizures inHeller
1995 (see Sensitivity analysis). Following reclassification, for the
remaining participants with generalised onset seizures (89) the
pooled HR was 0.51 (95% CI 0.21 to 1.24, P = 0.14), which
still indicates an advantage for phenytoin, but this advantage is no
longer statistically significant. Reclassifying these 29 participants
as having new-onset partial seizures, the pooled HR for 517 par-
ticipants is 1.11 (95% CI 0.82 to 1.50, P = 0.50), indicating a
slight advantage for carbamazepine, which is not statistically sig-
nificant. Following reclassification, the interaction between seizure
type (generalised versus partial onset) and treatment effect is no
longer statistically significant (Chi2 = 2.16, df = 1, P = 0.10, I
2= 62.3%). Results were similar when the 29 participants were
reclassified as uncertain seizure type (see Table 4).
Given that subgroup sizes are unbalanced (118 with generalised
seizures and 428 with partial seizures (as classified by the studies))
and that results may be confounded by misclassification of seizure
type in up to 29 participants, we cannot draw any firm conclusions
about an association between treatment and seizure type (i.e. that
participants with partial seizures are less likely to withdraw from
phenytoin and participants with generalised seizures are less likely
towithdraw from carbamazepine).We requiremore evidence, par-
ticularly from individuals with correctly classified generalised on-
set seizures to inform this analysis.
We judged evidence for ’Time to withdrawal of allocated treat-
ment’ to be of moderate quality according to GRADE criteria,
due to the potential impact of misclassification of seizure type on
the results (Summary of findings for the main comparison).
Time to achieve 12-month remission
For this outcome, a HR greater than one indicates a clinical ad-
vantage for phenytoin.
Data for 551 participants (99% of 558 randomised participants
fromDe Silva 1996, Heller 1995 andMattson 1985 (see Included
studies) and 45.8% of the 1192 participants from the 12 included
studies) from three out of four trials providing IPD were available
for the analysis of this outcome. Individuals were followed up for a
maximumof 12weeks inOgunrin 2005, so it could not contribute
to this outcome.
Two hundred and eighty-nine out of 551 participants (52%)
achieved 12-month remission: 155 out of 282 (55%) on pheny-
toin and 134 out of 269 (50%) on carbamazepine. The overall
pooled HR (for 551 participants, three trials) was 0.99 (95% CI
0.79 to 1.25, P = 0.95), suggesting no advantage for either drug.
There was no evidence of statistical heterogeneity between trials
(Chi2 = 1.49, df = 2, P = 0.47, I2= 0%, see Analysis 1.3).
Substantial statistical heterogeneity was present between the trials
for generalised onset seizures (I2= 73%, P = 0.06), so we calculated
HRs using the random-effects model. For participants with partial
onset seizures (n = 430, three trials), the pooledHRwas 0.94 (95%
CI 0.71 to 1.25, P = 0.68, random-effects), indicating no clear
advantage for either drug. For participants with generalised onset
seizures (n = 121, two trials), the pooled HR was 1.17 (95% CI
0.53 to 2.57, P = 0.70, random-effects), indicating an advantage
for phenytoin, which is not statistically significant. Overall, the
pooled HR (adjusted for seizure type for 551 participants, three
trials) was 1.01 (95% CI 0.78 to 1.31, P = 0.93, random-effects),
suggesting no clear advantage for either drug (see Analysis 1.4).
The test for interaction between seizure type (generalised versus
partial onset) and treatment effect was not significant (Chi2 = 0.25,
df = 1, P = 0.62, I2= 0%).
Following reclassification of the 29 participants aged 30 years
or older with new-onset generalised seizures in Heller 1995 (see
Sensitivity analysis), the pooled HR for 92 participants with gen-
eralised onset seizures was 1.44 (95% CI 0.90 to 2.31, P = 0.32,
I2= 0%, calculated with fixed-effect model), showing that all of
the heterogeneity in Analysis 1.4 is explained by misclassification
of participants with generalised onset seizures. The pooled esti-
mate for individuals with partial onset seizures and the overall es-
timate for all participants stratified by seizure type were similar to
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the original analysis, and our conclusions remain unchanged (see
Table 4).
In De Silva 1996, there is an indication that the proportional
hazards assumption may be violated (see Data synthesis); the P
value of time-varying covariate is 0.051 and visual inspection of the
cumulative incidence plot (Figure 12) shows crossing of the curves
at around 2500 days. In other words, up to 2500 days, participants
on phenytoin seem to be achieving 12-month remission quicker
than those on carbamazepine, but this changes after 2500 days;
however, participant numbers are small (15 participants at risk out
of 108 randomised), so small changes may be magnified at this
time.
Figure 12. Time to 12 month remission, deSilva 1996
As a sensitivity analysis, we fitted a piecewise Cox regression model
to investigate any change in treatment effect over time, assuming
proportional hazards within each interval. From the visual inspec-
tion of Figure 12, the follow-up period of De Silva 1996 is split
into two intervals; 0 to 2500 days and over 2500 days (maximum
follow-up was 4163 days). We can estimate separate HRs for each
interval as follows:
• For the interval 0 to 2500 days (88 events in 108
participants at risk) the HR is 1.29 (95% CI 0.84 to 1.96, P =
0.23), suggesting an advantage for phenytoin, which is not
statistically significant.
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• For the interval over 2500 days (five events in 15
participants at risk) the HR is 0.63 (95% CI 0.25 to 1.57, P =
0.32), suggesting an advantage for carbamazepine, which is not
statistically significant.
These results suggest some indication of a change in treatment
effect over time, with an advantage for phenytoin earlier on in the
study, changing to an advantage for carbamazepine later in the
study. However, CIs of estimates are wide, particularly for the HR
after 2500 days due to small numbers of events and participants at
risk, so we do not have statistically significant evidence to support
the hypothesis of a change in treatment effect over time for De
Silva 1996, and conclude that the change of direction in effect at
around 2500 days is likely to be due to small participant numbers
after this time.
We judged the evidence for ’Time to 12-month remission’ to be of
low to moderate quality according to GRADE criteria, due to the
potential impact of misclassification of seizure type on the results
and heterogeneity between studies (Summary of findings 2).
Time to achieve six-month remission
For this outcome, a HR greater than one indicates a clinical ad-
vantage for phenytoin.
Data for 551 participants (99% of 558 randomised participants
fromDe Silva 1996, Heller 1995 andMattson 1985 (see Included
studies) and 45.8% of the 1192 participants from the 12 included
studies) from three out of four trials providing IPD were available
for the analysis of this outcome. Individuals were followed up for a
maximumof 12weeks inOgunrin 2005, so it could not contribute
to this outcome.
Three hundred and thirty-eight out of 551 participants (61%)
achieved six-month remission: 179out of 282 (63%) on phenytoin
and 159 out of 269 (59%) on carbamazepine. The overall pooled
HR (for 551 participants, three trials) was 1.08 (95% CI 0.87
to 1.34, P = 0.46), suggesting no clear advantage for either drug.
There was no evidence of statistical heterogeneity between trials
(Chi2 = 0.35, df = 2, P = 0.84, I2= 0%, see Analysis 1.5).
For the participants with partial onset seizures (n = 430, three tri-
als), the pooled HR was 1.02 (95% CI 0.79 to 1.33, P = 0.85),
indicating no clear advantage for either drug. For the participants
with generalised onset seizures (n = 121, two trials), the pooled
HR was 1.30 (95% CI 0.89 to 1.92, P = 0.18), indicating an ad-
vantage for phenytoin, which is not statistically significant. Less
statistical heterogeneity was present between the trials for gener-
alised onset seizures compared to the analysis of time to 12-month
remission (I2 = 39%, P = 0.20), so we present HRs from a fixed-
effect model. Overall, the pooled HR (adjusted for epilepsy type
for 551 participants, three trials) was 1.11 (95% CI 0.89 to 1.37,
P = 0.36, three trials), suggesting a slight advantage for phenytoin,
which is not statistically significant. The test for interaction be-
tween seizure type (generalised versus partial onset) and treatment
effect was not significant (Chi2 = 1.03, df = 1, P = 0.31, I2 = 3.4%,
see Analysis 1.6).
Following reclassification of the 29 participants aged 30 years
or older with new-onset generalised seizures in Heller 1995 (see
Sensitivity analysis), the pooled HR for 92 participants with gen-
eralised onset seizures was 1.69 (95% CI 1.07 to 2.27, P = 0.02,
I2 = 0%), showing a larger and statistically significant advantage
for phenytoin. Reclassifying these 29 participants as having new-
onset partial seizures, the pooled HR for 517 participants is 1.02
(95% CI 0.80 to 1.31), similar to Analysis 1.6, indicating no clear
advantage for either drug. Following reclassification, the test for
interaction between seizure type (generalised versus partial onset)
and treatment effect was borderline statistically significant (Chi2
= 3.63, df = 1, P = 0.06, I2 = 72.5%). Results were similar when
the 29 participants were reclassified as uncertain seizure type (see
Table 4).
However, as in the analysis of our primary outcome ’Time to with-
drawal of allocated treatment’, as subgroup sizes are unbalanced
(118 with generalised seizures and 428 with partial seizures, as
classified by the studies) and as results may be confounded by mis-
classification of seizure type in up to 29 participants, we cannot
draw any firm conclusions about an association between treatment
and seizure type (i.e. that participants achieve six-month remission
quicker on phenytoin than on carbamazepine). Again, we require
more evidence, particularly from individuals with correctly classi-
fied generalised onset seizures to inform this analysis.
In De Silva 1996, there is an indication that the proportional
hazards assumption may be violated (see Data synthesis); the P
value of time-varying covariate is 0.066 and visual inspection of
the cumulative incidence plot (Figure 13) shows crossing of the
curves at several points at around 1000 days, 1750 days and 3500
days, suggesting several changes in treatment effect over time. As
in the sensitivity analysis of De Silva 1996 in ’Time to 12-month
remission’, after 1000 days participant numbers are small (18 par-
ticipants at risk out of 108 randomised), so small changes may be
magnified in the later stages of study follow-up.
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Figure 13. Time to 6 month remission, deSilva 1996
As a sensitivity analysis, we fitted a piecewise Cox regression model
to investigate any change in treatment effect over time, assuming
proportional hazards within each interval. From the visual inspec-
tion of Figure 13, the follow-up period of De Silva 1996 is split
into three intervals; 0 to 1000 days, 1000 to 1750 days, and over
1750 days (maximum follow-up is 4163 days). We did not con-
sider an interval of 3500 days to the end of the study, due to very
small participant numbers at this time (three participants at risk).
We can estimate separate HRs for each interval as follows:
• For the interval 0 to 1000 days (87 events in 108
participants at risk) the HR is 1.18 (95% CI 0.77 to 1.80, P =
0.44), suggesting an advantage for phenytoin, which is not
statistically significant.
• For the interval 1000 to 1750 days (three events in 18
participants at risk) the HR is 1.26 (95% CI 0.37 to 4.18, P =
0.71), again suggesting an advantage for phenytoin, which is not
statistically significant.
• For intervals over 1750 days (five events in 14 participants
at risk) the HR is 0.76 (95% CI 0.41 to 1.39), suggesting an
advantage for carbamazepine, which is not statistically
significant.
As above, these results suggest some indication of a change in
treatment effect over time, with an advantage for phenytoin earlier
on in the study, changing to an advantage for carbamazepine later
in the study. However, CIs of estimates are again wide, due to
small participant numbers in the later two intervals, so we do not
have statistically significant evidence to support the hypothesis of
a change in treatment effect over time for De Silva 1996, and
conclude that the apparent changes of direction in effect at later
stages of the study are likely to be due to small participant numbers.
We judged evidence for ’Time to six-month remission’ to be of
moderate quality according to GRADE criteria, due to the po-
tential impact of misclassification of seizure type on the results
(Summary of findings 2).
Time to first seizure post-randomisation
For this outcome, a HR greater than one indicates a clinical ad-
vantage for carbamazepine.
Data for 582 participants (99% of 558 randomised participants
fromDe Silva 1996, Heller 1995 andMattson 1985 (see Included
studies), 100% from Ogunrin 2005, and 49% of the 1192 partic-
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ipants from the 12 included studies) from all four trials providing
IPD were available for the analysis of this outcome.
Three hundred and eighty-three out of 582 participants (66%)
experienced a recurrence of seizures: 192 out of 297 (64%) on
phenytoin and 191 out of 285 on carbamazepine (67%). The over-
all pooled HR (for 582 participants, four trials) was 0.88 (95% CI
0.72 to 1.08, P = 0.21), suggesting a slight advantage for pheny-
toin, which is not statistically significant. There was little evidence
of statistical heterogeneity between trials (Chi2 = 4.53, df = 3, P
= 0.21, I2 = 34%, see Analysis 1.7).
For the participants with partial onset seizures (n = 432, four tri-
als), the pooled HR was 0.86 (95% CI 0.68 to 1.08, P = 0.20), in-
dicating a slight advantage for phenytoin, which is not statistically
significant. For the participants with generalised onset seizures (n
= 150, three trials), the pooledHRwas 0.84 (95%CI 0.57 to 1.24,
P = 0.38), again indicating a slight advantage for phenytoin, which
is not statistically significant. Again, there was some statistical het-
erogeneity between trials for generalised onset seizures (I2 = 45%,
P = 0.16). Overall, the pooled HR (adjusted for epilepsy type for
582 participants, four trials) was 0.85 (95% CI 0.70 to 1.04, P =
0.38), suggesting a slight advantage for phenytoin, which is not
statistically significant. The test for interaction between seizure
type (generalised versus partial onset) and treatment effect was not
significant (Chi2 = 0.01, df = 1, P = 0.93, I2 = 0%, see Analysis
1.8).
Following reclassification of the 48 participants aged 30 years or
older with new-onset generalised seizures in Heller 1995 and
Ogunrin 2005 (see Sensitivity analysis), results were very similar
and conclusions were unchanged (see Table 4). Unlike in analysis
of ’Time to 12-month remission’, heterogeneity for participants
with generalised onset seizures in Analysis 1.8 is barely reduced
following reclassification of seizure type (I2 is reduced from 45%
to 42% following reclassification).
Following visual inspection of the forest plot in Analysis 1.8 (gen-
eralised epilepsy type), there is a difference in the direction of ef-
fects of the three studies, with De Silva 1996 and Ogunrin 2005
showing an advantage for phenytoin, which is not statistically sig-
nificant, and Heller 1995 showing a slight advantage for carba-
mazepine, which is not statistically significant).
From correspondence with the study authors, we know that De
Silva 1996 andHeller 1995 were conducted under the same proto-
col and therefore trial characteristics should be homogeneous; the
only difference between the two studies is within the age groups
recruited (De Silva 1996 recruited children only and Heller 1995
recruited adults only). We therefore performed a further subgroup
analysis by adult versus paediatric studies (Ogunrin 2005 also re-
cruited adults only). For 101 adults with generalised onset seizures,
the pooled HR was 1.02 (95% CI 0.62 to 1.68, P = 0.94), indi-
cating no clear advantage for either drug, and for 49 children with
generalised onset seizures in De Silva 1996 the HR was 0.63 (95%
CI 0.34 to 1.16, P = 0.14), indicating an advantage for phenytoin,
which is not statistically significant.
The test for interaction between age groups recruited (adults versus
children) and treatment effect was not significant (Chi2 = 1.45, df
= 1, P = 0.23, I2 = 30.9%). However, participant numbers with
generalised onset seizures are quite limited in this review, so we
may not have had the power to detect a difference between age
groups.
In Ogunrin 2005 there is an indication that the proportional haz-
ards assumption may be violated (see Data synthesis); the P value
of time-varying covariate is 0.02 and visual inspection of the cu-
mulative incidence plot (Figure 14) shows clear crossing of the
curves at around 10 days. In other words, up to 10 days, more
participants seem to be having seizure recurrence on phenytoin,
but this changes to those on carbamazepine after 10 days.
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Figure 14. Time to first seizure, Ogunrin 2005
As a sensitivity analysis, we fitted a piecewise Cox regression model
to investigate any change in treatment effect over time, assuming
proportional hazards within each interval. From the visual inspec-
tion of Figure 14, the follow-up period of Ogunrin 2005 is split
into two intervals; 0 to 10 days and over 10 days (maximum fol-
low-up is 84 days). We can estimate separate HRs for each interval
as follows:
• For the interval 0 to 10 days (13 events in 37 participants at
risk) the HR is 1.49 (95% CI 0.45 to 4.88, P = 0.51), suggesting
an advantage for carbamazepine, which is not statistically
significant.
• For intervals over 10 days (eight events in 24 participants at
risk) the HR is 32 (95% CI 0.11 to 0.91, P = 0.03), suggesting a
large statistically significant advantage for phenytoin. Visual
inspection of Figure 14 also shows a clear advantage for
phenytoin after 10 days.
These results suggest some indication of a change in treatment
effect over time, with a slight early advantage for carbamazepine,
changing to a large statistically significant advantage for pheny-
toin later in the study, and support the hypothesis of a change in
treatment effect over time for Ogunrin 2005. Ogunrin 2005 is by
far the shortest of the studies for which we have IPD (maximum
follow-up was 84 days in Ogunrin 2005 compared to maximum
follow-up of 3995 days in Heller 1995, 4589 days in De Silva
1996 and 1838 days inMattson 1985), and we did not find statis-
tically significant evidence of a difference between carbamazepine
and phenytoin for ’Time to first seizure after randomisation’ in
any of the three studies with a longer duration (see Analysis 1.7).
The apparent large advantage for phenytoin from 10 to 84 days in
Ogunrin 2005,may therefore have reduced in size or even changed
direction to favour carbamazepine if this study had continued for
a longer duration.
We judged evidence for ’Time to first seizure after randomisation’
to be of low to moderate quality according to GRADE criteria,
due to the potential impact of misclassification of seizure type on
the results and imprecision of the effect sizes (Summary of findings
3).
Adverse events
We extracted all reported information related to adverse events
from the study publications. Miura 1993 and Ravi Sudhir 1995
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did not report any information on adverse events and we are un-
certain without access to protocols if these data were collected (see
Selective reporting (reporting bias)). See Table 5 for details of all
adverse event data provided in the other 10 studies included in
this review. In summary, the adverse events reported by two or
more studies in this review are as follows:
For carbamazepine
• Gastrointestinal side effects including abdominal pain,
nausea and vomiting: (Cereghino 1974; Forsythe 1991; Mattson
1985; Ramsay 1983).
• Drowsiness/tiredness/fatigue/sedation: (Callaghan 1985;
De Silva 1996; Forsythe 1991; Heller 1995; Pulliainen 1994;
Ramsay 1983).
• Rash: (Callaghan 1985; Heller 1995; Mattson 1985;
Ogunrin 2005).
• Decreased libido, or impotence, or both: (Mattson 1985;
Ramsay 1983).
• Headaches: (Forsythe 1991; Heller 1995; Ramsay 1983).
• Motor disturbance (including ataxia, incoordination,
nystagmus, tremor, slowing of mental function, inattention,
psychomotor retardation): (Forsythe 1991; Mattson 1985;
Ogunrin 2005; Ramsay 1983).
• Dysmorphic and idiosyncratic side effects (gum
hypertrophy, hirsutism, acne, other skin problems): (Mattson
1985; Pulliainen 1994; Ramsay 1983).
• Cognitive side effects and impairments, including
depression and memory problems: (Heller 1995; Ogunrin 2005;
Pulliainen 1994; Ramsay 1983).
For phenytoin
• Gastrointestinal side effects including abdominal pain,
nausea and vomiting: (Cereghino 1974; Mattson 1985; Ramsay
1983).
• Drowsiness/tiredness/fatigue/sedation: (De Silva 1996;
Pulliainen 1994; Ramsay 1983).
• Rash: (Callaghan 1985; De Silva 1996; Mattson 1985;
Ogunrin 2005).
• Decreased libido, or impotence, or both: (Mattson 1985;
Ramsay 1983).
• Motor disturbance (including ataxia, incoordination,
nystagmus, tremor, slowing of mental function, inattention,
psychomotor retardation): (Callaghan 1985; Mattson 1985;
Ogunrin 2005; Ramsay 1983).
• Dysmorphic and idiosyncratic side effects (gum
hypertrophy, hirsutism, acne, other skin problems): (Callaghan
1985; De Silva 1996; Mattson 1985; Ramsay 1983).
• Cognitive side effects and impairments, including
depression and memory problems: (Forsythe 1991; Ogunrin
2005; Ramsay 1983).
Because of the differences in methods of reporting adverse event
data across the studies (see Table 5), it is difficult to summarise the
’most common’ adverse events overall across the 12 studies, or to
deduce whether carbamazepine or phenytoin are most associated
with specific adverse events. Adverse event data for individuals
were not included in the original IPD requests for earlier versions
of this review, but will be sought in all future IPD requests.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Carbamazepine compared with phenytoin for epilepsy
Patient or population: adults and children with new-onset part ial or generalised epilepsy
Settings: outpat ients
Intervention: carbamazepine
Comparison: phenytoin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)1
No. of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Phenytoin Carbamazepine
Time to 12-month re-
m ission
- strat if ied by epilepsy
type
Range of follow-up (all
part icipants): 0 days to
4222 days
55 per 100 55 per 100 (46 to 65) HR 1.01
(0.78 to 1.31)
551 (3 studies) ⊕⊕⊕©
moderate2,3
HR > 1 indicates a clini-
cal
advantage for phenytoin
Time to 12-month re-
m ission
- part ial epilepsy
Range of follow-up (all
part icipants):0 days to
4222 days
47 per 100 45 per 100 (36 to 55) HR 0.94
(0.71 to 1.25)
430 (3 studies) ⊕⊕⊕©
moderate2,3
HR > 1 indicates a clini-
cal
advantage for phenytoin
Time to 12-month re-
m ission
- generalised epilepsy
Range of follow-up (all
part icipants): 7 days to
4163 days
85 per 100 88 per 100 (63 to 99) HR 1.174
(0.53 to 2.57)
121 (2 studies) ⊕⊕©©
low2,3,4
HR > 1 indicates a clini-
cal
advantage for phenytoin
3
2
C
a
rb
a
m
a
z
e
p
in
e
v
e
rsu
s
p
h
e
n
y
to
in
m
o
n
o
th
e
ra
p
y
fo
r
e
p
ile
p
sy
:
a
n
in
d
iv
id
u
a
l
p
a
rtic
ip
a
n
t
d
a
ta
re
v
ie
w
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Time to 6-month remis-
sion
- strat if ied by epilepsy
type
Range of follow-up (all
part icipants): 0 days to
4222 days
63 per 100 67 per 100 (59 to 75) HR 1.11
(0.89 to 1.37)
551 (3 studies) ⊕⊕⊕©
moderate2,3
HR >1 indicates a clini-
cal
advantage for phenytoin
Time to 6-month remis-
sion
- part ial epilepsy
Range of follow-up (all
part icipants): 0 days to
4222 days
56 per 100 56 per 100 (47 to 66) HR 1.02
(0.79 to 1.33)
430 (3 studies) ⊕⊕⊕©
moderate2,3
HR > 1 indicates a clini-
cal
advantage for phenytoin
Time to 6-month remis-
sion
- generalised epilepsy
Range of follow-up (all
part icipants): 7 days to
4163 days
93 per 100 97 per 100 (91 to 99) HR 1.30
(0.89 to 1.92)
121 (2 studies) ⊕⊕⊕©
moderate2,3
HR > 1 indicates a clini-
cal
advantage for phenytoin
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The assumed risk is calculated as the event rate in the Phenytoin
treatment group The corresponding risk in the carbamazepine treatment group (and its 95% CI) is based on the assumed risk in the comparison group and the relat ive ef fect
of the intervent ion (and its 95% CI)
The corresponding risk is calculated as the assumed risk x the relat ive risk (RR) of the intervent ion where RR = (1 - exp(HR x ln(1 - assumed risk)) ) / assumed risk
CI: Conf idence interval; HR: Hazard Ratio; exp: exponent ial
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Pooled HR for all part icipants adjusted for seizure type.
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2Risk of bias unclear for one element of all of the three studies included in the analysis. De Silva 1996 and Heller 1995 are
open-label and it is unclear whether the lack of masking impacted upon the results; and we do not know how allocat ion was
concealed in Mattson 1985.
329 adult part icipants in Heller 1995 may have had their seizure type wrongly classif ied as generalised onset; sensit ivity
analyses show misclassif icat ion may have had an impact on results and conclusions regarding an associat ion between
treatment and seizure type.
4Time to 12-month remission for 121 individuals with generalised seizures calculated with random-ef fects model due to
heterogeneity between part icipants. This heterogeneity is likely to be due to misclassif icat ion of seizure type (see footnote
3).
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Carbamazepine compared with phenytoin for epilepsy
Patient or population: adults and children with new-onset part ial or generalised epilepsy
Settings: outpat ients
Intervention: carbamazepine
Comparison: phenytoin
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)1
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Phenytoin Carbamazepine
Time to f irst seizure
- strat if ied by epilepsy
type
Range of follow-up (all
part icipants): 0 days to
4589 days
65 per 100 71 per 100 (63 to 77) HR 0.85
(0.70 to 1.04)
582
(4 studies)
⊕⊕©©
low2,3,4
HR > 1 indicates a clini-
cal
advantage for carba-
mazepine
Time to f irst seizure
- part ial epilepsy
Range of follow-up (all
part icipants): 0 days to
4589 days
63 per 100 68 per 100 (60 to 77) HR 0.86
(0.68 to 1.08)
432
(4 studies)
⊕⊕©©
low2,3,4
HR > 1 indicates a clini-
cal
advantage for carba-
mazepine
Time to f irst seizure
- generalised epilepsy
Range of follow-up (all
part icipants): 2 days to
4070 days
69 per 100 75 per 100 (61 to 87) HR 0.84
(0.57 to 1.24)
150
(3 studies)
⊕⊕©©
low2,3,4
HR > 1 indicates a clini-
cal
advantage for carba-
mazepine
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The assumed risk is calculated as the event rate in the Phenytoin
treatment group The corresponding risk in the carbamazepine treatment group (and its 95% CI) is based on the assumed risk in the comparison group and the relat ive ef fect
of the intervent ion (and its 95% CI)
The corresponding risk is calculated as the assumed risk x the relat ive risk (RR) of the intervent ion where RR = (1 - exp(HR x ln(1 - assumed risk)) ) / assumed risk
CI: Conf idence interval; HR: Hazard Ratio; exp: exponent ial
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Pooled HR for all part icipants adjusted for seizure type.
2Risk of bias unclear for one element of all of the three studies included in the analysis. De Silva 1996 and Heller 1995 are
open-label and it is unclear whether the lack of masking impacted upon the results; and we do not know how allocat ion was
concealed in Mattson 1985.
348 adult part icipants in Heller 1995 and Ogunrin 2005 may have had their seizure type wrongly classif ied as generalised
onset; sensit ivity analyses show misclassif icat ion is unlikely to have had an impact on results and conclusions.
4Ogunrin 2005 is a short study (12 weeks) and has a small sample size of 37 compared to the other three studies of durat ion
3 - 10 years and sample sizes of around 100 to 300 part icipants (De Silva 1996; Heller 1995; Mattson 1985). Ogunrin 2005 is
less precise with wide CIs, and there is evidence that the treatment ef fect in this study changes over t ime.
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D I S C U S S I O N
Summary of main results
The results of this review demonstrate a statistically significant ad-
vantage for phenytoin over carbamazepine for the 118 individuals
with new-onset generalised tonic-clonic seizures for the primary
global outcome ’Time to withdrawal of allocated treatment’; how-
ever, this result is likely to have been confounded by misclassifi-
cation of seizure type for 29 individuals and when this misclassi-
fication is taken into account in sensitivity analysis, the advantage
for phenytoin is no longer statistically significant. Results for 428
individuals with new-onset partial seizures suggest an advantage
for carbamazepine, which is not statistically significant. Overall,
for the 546 individuals contributing withdrawal data to this re-
view, we found no statistically significant evidence for a difference
between carbamazepine and phenytoin.
Results of this review also show that among 589 participants re-
cruited in the USA and Europe, carbamazepine is around twice
as likely to be withdrawn than phenytoin for adverse events, de-
spite concerns about serious adverse events leading to the replace-
ment of phenytoin with carbamazepine or lamotrigine as a first-
line drug for partial onset seizures across much of the USA and
Europe (NICE 2012).
Our primary outcome is a measure of effectiveness influenced by
both the relative efficacy of the two drugs and differences in tol-
erability and safety, so a difference in efficacy in one direction
may be confounded by a difference in tolerability in the other. It
may therefore not be surprising that any estimated differences are
small, and the results of this review cannot exclude clinically im-
portant differences between the drugs and between seizure types.
Furthermore, the largest study, contributing over 60% of partic-
ipants to the analysis of our primary outcome, recruited partici-
pants with partial onset seizures only, so the subgroups of partici-
pants by seizure type are unbalanced in size (428 participants with
partial seizures versus 118 with generalised seizures), resulting in
less precise results and wide CIs for individuals with generalised
onset seizures.
Similarly for the secondary outcomes ’Time to 12-month remis-
sion’, ’Time to six-month remission’, and ’Time to first seizure’,
we found no statistically significant differences between pheny-
toin and carbamazepine, for participants overall or by seizure type.
However, subgroups of participants by seizure type are again un-
balanced in size, and misclassification of seizure types may have
confounded analyses. More evidence is needed, particularly from
individuals with correctly classified generalised seizures, to inform
all of the outcomes of this review.
For all outcomes in this review we would recommend caution
in the interpretation of the results (see Overall completeness and
applicability of evidence), and we would not recommend basing a
choice between these two drugs on the results of this review alone.
Overall completeness and applicability of
evidence
We believe our systematic electronic searches identified all rele-
vant evidence for this review. We have gratefully received indi-
vidual participant data (IPD) for 595 individuals (50% of indi-
viduals from all eligible trials) from the authors of four trials (De
Silva 1996; Heller 1995; Mattson 1985; Ogunrin 2005), which
included a comparison of phenytoin versus carbamazepine for the
treatment of epilepsy.However, 574 individuals (48%) from seven
relevant trials (Callaghan 1985; Cereghino 1974; Czapinski 1997;
Miura 1993; Pulliainen 1994; Ramsay 1983; Ravi Sudhir 1995)
could not be included in any analysis as IPD were not available
and outcomes of interest were not reported in the published re-
ports. Sufficient data for 23 individuals (2%) were published in
one trial (Forsythe 1991) to contribute to analysis for the primary
outcome ’Time to withdrawal of allocated treatment’, but insuffi-
cient data were available to include these individuals in the analy-
ses by seizure type and the analyses of other outcomes. Having to
exclude data from half of eligible participants due to lack of IPD
and insufficient reporting in study publications is likely to have
impacted on the applicability of the evidence, but it is difficult to
quantify exactly how large this impact was on the results of this
review (see Potential biases in the review process).
Three trials contributing around 80% of the participant data to
this review recruited adults only (Heller 1995; Mattson 1985;
Ogunrin 2005); the remaining study was a paediatric trial (De
Silva 1996). Also, the largest single trial contributing over half of
the participant data to this review (Mattson 1985) recruited indi-
viduals with partial onset seizures only, so that only around 25% of
participants included in this review were experiencing generalised
onset seizures. Furthermore, there is evidence within this review
to suggest that up to 30% of individuals with new-onset gener-
alised seizures may have had their seizure type misclassified. For
these reasons, the results of this review may not be fully generalis-
able to children or to individuals with generalised onset seizures,
and more evidence is required from participants with generalised
seizure types.
Quality of the evidence
The four trials for which IPD were available were generally at
low risk of bias (see Figure 3). Three of the trials contributing
around half of the participant data to this review described ade-
quate methods of randomisation and allocation concealment (De
Silva 1996; Heller 1995; Ogunrin 2005), but the largest single
trial contributing 54% of participant data (Mattson 1985) did not
describe themethod of randomisation and allocation concealment
used, and this information was not available from study authors.
We are uncertain whether this lack of information has impacted
on the results of this review. See Summary of findings for the main
comparison; Summary of findings 2; Summary of findings 3 for
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GRADE assessments of the quality of the evidence.
Two of the trials providing IPD blinded participants and outcome
assessors (Mattson 1985; Ogunrin 2005) and the other two trials
(De Silva 1996; Heller 1995) were designed as pragmatic open-
label trials, as masking of treatment would not be “practicable or
ethical“, would “undermine compliance” and would have “intro-
duced bias due to a very large drop-out rate.” For the three tri-
als providing withdrawal information, the withdrawal rate in the
double-blinded trial (Mattson 1985) was 40%, and withdrawal
rates were 36% and 24% inDe Silva 1996 andHeller 1995 respec-
tively (29.5% withdrawal rate overall in the two open-label stud-
ies, which is statistically significantly lower than the withdrawal
rate in the double-blind study; P = 0.009). It is therefore debatable
whether a double-blind design is the most appropriate for trials
of monotherapy in epilepsy of long duration and whether such a
design does have an impact upon the dropout rate and therefore
on the results of the trial.
Further differences between the studies were in the population
recruited (age of participants and seizure types). We discuss these
differences below in Overall completeness and applicability of
evidence.
Trials for which no IPD were available were generally of poorer
quality than those for whichwewere had IPD,with two studies de-
scribing inadequate methods of randomisation or allocation con-
cealment (Callaghan 1985; Forsythe 1991), three trials present-
ing incomplete outcome data following exclusion of participants
(Pulliainen 1994; Ramsay 1983; Ravi Sudhir 1995), one study us-
ing an inadequate cross-over design for investigating monotherapy
treatments (Cereghino 1974), and two trials providing very lim-
ited information on trial methodology, available only in abstract
or summary form (Czapinski 1997; Miura 1993).
Potential biases in the review process
We were provided with IPD for 595 out of 1192 eligible partici-
pants (50%) from four out of 12 studies included; we conducted
all analyses as IPD analyses. Such an approach has many advan-
tages, such as allowing us to standardise definitions of outcomes
across trials, and attrition and reporting biases being reduced as
we can perform additional analyses and calculate additional out-
comes from unpublished data. For the outcomes we used in this
review which are of a time-to-event nature, an IPD approach is
considered to be the ‘gold standard’ approach to analysis (Parmar
1998).
However, despite the advantages of this approach, for reasons out
of our control we were not able to obtain IPD for 597 participants
from eight eligible studies and no aggregate data were available for
our outcomes of interest in study publications. We therefore had
to exclude around half of eligible participants from our analyses,
which may have introduced bias into the review.
From the results reported in these eight studies (see Table 1 for
narrative description of the results of each study), only one study
showed a statistically significant difference in efficacy between car-
bamazepine and phenytoin for participants with generalised onset
seizures (73% seizure-free with phenytoin versus 39% seizure-free
with carbamazepine, Callaghan 1985). There was no difference
between treatments for participants with partial onset seizures (P =
0.006). Some significant differences between carbamazepine and
phenytoin in terms of specific adverse events and cognitive adverse
events were also reported (see Table 1). However, no consistent
differences in efficacy or tolerability were reported in these eight
studies, so it is unclear whether the exclusion of these studies from
our meta-analysis has impacted upon our results and conclusions.
Furthermore, six of the eight studies that we could not include
in meta-analysis were at high risk of bias for at least one method-
ological aspect (see Figure 3), so inclusion of these data may have
introduced bias into our results.
We have good evidence from previous reviews conducted by the
Cochrane Epilepsy Group (Marson 2000; Nolan 2013b) that mis-
classification of seizure type is an important issue in epilepsy tri-
als. We believe that the results of the original trials and hence
the results of this meta-analysis may have been confounded by
classification bias, particularly the 48 individuals from two trials
(Heller1995;Ogunrin 2005) classifiedwith new-onset generalised
seizures over the age of 30 (Malafosse 1994). Sensitivity analysis
to investigate potential misclassification of these 48 individuals
changes our conclusion for two outcomes (’Time to withdrawal
of allocated treatment’ and ’Time to six-month remission’), and
explains all heterogeneity among individuals with generalised on-
set seizures for the outcome ’Time to 12-month remission’. Both
studies with potentially misclassified participants used the Inter-
national League Against Epilepsy (ILAE) classification of 1981
(Commission 1981) to classify generalised onset and partial onset
seizures. Heller 1995 was initiated before the publication of the re-
vised ILAE classification in 1989 (Commission 1989), so some in-
dividuals in Heller 1995 may have been classified correctly accord-
ing toCommission 1981 butmisclassified by the revised Commis-
sion 1989. Ogunrin 2005 was initiated around 10 years after the
publication of Commission 1989, but this study was conducted
in Nigeria, a low-income country without access to the same facil-
ities as trials conducted in the USA and Europe; seizure types were
therefore classified clinically, and electroencephalographs (EEGs)/
magnetic resonance imaging (MRI) were not required for diag-
nosis of epilepsy. Clinical classification may have contributed to
potential misclassification in this study.
Finally, we made some assumptions in the statistical methodology
used in this review. Firstly, when we received only follow-up dates
and seizure frequencies, we used linear interpolation to estimate
seizure times. We are aware that an individual’s seizure patterns
may be non-linear; we therefore recommend caution when inter-
preting the numerical results of the seizure-related outcomes.
Further, the statistical methodology used in this review made
an assumption that the treatment effect for each outcome did
not change over time (proportional hazards assumption, see Data
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synthesis). For three of the outcomes, there was evidence that this
assumption may have been violated for one of the trials. Sensitivity
analysis showed that changes in treatment effect tended to occur
in the later stages of the studies when small participant numbers
were being followed up, so small changes in treatment effect would
be magnified. However, we are aware that in studies of long du-
ration (De Silva 1996; Heller 1995; Mattson 1985 followed up
participants for between three and 10 years), the assumption of
treatment effect remaining constant over time is unlikely to be ap-
propriate, so if more data can be made available to us for updates
of this review, we would like to perform statistical analyses which
allow for treatment effects to vary over time.
Agreements and disagreements with other
studies or reviews
No single trial included in this review has found convincing dif-
ferences between phenytoin and carbamazepine with respect to
seizure control or seizure type.However,CIs around estimates have
been wide and equivalence cannot be inferred. Furthermore, this
systematic review and meta-analysis has not found any statistically
significant differences between phenytoin and carbamazepine for
any of the outcome measures for all included participants. The
results of this review suggest a potential advantage for phenytoin
over carbamazepine for our primary global outcome ’Time towith-
drawal of allocated treatment’ for individuals with generalised on-
set seizures, but this result may have been confounded by misclas-
sification of seizure type.
To our knowledge, this is the only systematic review and meta-
analysiswhich compares phenytoin and carbamazepinemonother-
apies for partial onset seizures and generalised onset tonic-clonic
seizures. A network meta-analysis has been published (Tudur
Smith 2007), comparing all direct and indirect evidence from
phenytoin, carbamazepine and other standard and new antiepilep-
tic drugs licensed for monotherapy, and found no statistically sig-
nificant differences between phenytoin and carbamazepine for the
outcomes specified in this review; this agrees with the findings of
this review. The network meta-analysis is currently being updated
to include more recently published studies such as Ogunrin 2005,
so we will compare the results of this review with the updated
network meta-analysis.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Current guidelines recommend carbamazepine or lamotrigine as
first-line treatment for adults and children with new-onset partial
seizures and sodium valproate for adults and children with new-
onset generalised seizures (NICE 2012).
The results of this systematic review do not provide any conclusive
evidence for a difference between carbamazepine and phenytoin
in terms of efficacy for individuals with partial onset or generalised
onset seizures. Phenytoin is no longer considered to be a first-line
treatment in the USA and Europe, due to concerns over adverse
events (Wallace 1997; Wilder 1995), but the results of this review
show that among 589 participants from four studies conducted in
the USA and Europe carbamazepine was around twice as likely to
be withdrawn as phenytoin due to adverse events. Furthermore,
from a study conducted inAfrica (Nigeria), where phenytoin is still
commonly used as a first-line treatment due to low cost, no par-
ticipants withdrew from either carbamazepine or phenytoin due
to adverse events. The results of this review provide no evidence
in favour of the withdrawal of phenytoin as a first-line treatment.
The results of this review do not provide sufficient evidence to
choose between carbamazepine and phenytoin for the treatment
of partial onset or generalised onset seizures.
Implications for research
We found few consistent differences in efficacy between the two
standard antiepileptic drugs in individual trials and from the
pooled results of this review. If differences in efficacy do exist across
heterogeneous populations of individuals such as those studied
here, then it is likely that these differences are small. It has been
argued that future comparative antiepileptic drug trials should be
powered to establish equivalence (Jones 1996), and therefore be
capable of detecting what is considered to be the smallest impor-
tant clinical difference.
This review highlights the need for future antiepileptic drug
monotherapy trials that recruit individuals of all ages with spe-
cific epilepsy syndromes, to be designed and powered to detect
a difference between particular antiepileptic drugs. An approach
likely to reflect and inform clinical practice, as well as being sta-
tistically powerful, would be to recruit heterogeneous populations
for whom epilepsy syndromes have been adequately defined, with
testing for interactions between treatment and epilepsy syndrome.
In view of the potential problems of misclassification, syndromes
will have to be well defined, with adequate checking mechanisms
to ensure that classifications are accurate, and with a system to
recognise uncertainty surrounding epilepsy syndromes in individ-
uals within trials.
Consideration is also required in the design of a trial about whether
to blind participants and outcome assessors to treatment alloca-
tion. Results of this review show that withdrawal rates are higher
in a double-blind trial compared to open-label, more pragmatic
trials. However, in trials involving drugs with documented adverse
event profiles, such as phenytoin, masking of treatment may be
important to avoid preconceptions about the drug being more
likely to be associated with serious adverse events, which were not
shown in the results of this review.
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The choice of outcomes at the design stage of a trial, and the pre-
sentation of the results of outcomes, particularly of a time-to event
nature, require very careful consideration. While an outcomemea-
suring efficacy (seizure control), and an outcome measuring toler-
ability (adverse events) are recorded in the majority of studies of a
monotherapy design, there is little uniformity between the defini-
tion of the outcomes and the reporting of the summary statistics
related to the outcomes (Nolan 2013a), making an aggregate data
approach to meta-analysis in reviews of monotherapy studies im-
possible. Where trial authors cannot or will not make IPD avail-
able for analysis, we are left with no choice but to exclude a pro-
portion of relevant evidence from the review, which will impact
upon the interpretation of results of the review and applicability of
the evidence and conclusions. The International League Against
Epilepsy (Commission 1998; ILAE 2006) recommends that stud-
ies of a monotherapy design should adopt a primary effectiveness
outcome of ’Time to withdrawal of allocated treatment (retention
time)’ and should be of at least 48 weeks duration to allow for
assessment of longer-term outcomes such as remission. If studies
followed these recommendations, an aggregate data approach to
meta-analysis may be feasible, reducing the resources and time re-
quired for an IPD approach.
A network meta-analysis has been published (Tudur Smith 2007),
comparing all direct and indirect evidence from phenytoin, car-
bamazepine and other standard and new antiepileptic drugs li-
censed for monotherapy. This review and the network meta-anal-
ysis will be updated as more information becomes available. How-
ever, we acknowledge that as phenytoin is no longer considered to
be a first-line agent for newly-diagnosed individuals, (with newer
agents such as lamotrigine and levetiracetam replacing its use), it
is unlikely that substantial new evidence will become available for
this review.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Callaghan 1985
Methods Single-centre, randomised, parallel-group trial of people referred for assessment at Cork
Regional Hospital, Ireland
Three treatment arms: carbamazepine, phenytoin, sodium valproate
Dates conducted: Not stated
Participants Adults and children with a minimum of 2 untreated generalised or partial seizures in the
6 months preceding the study
Number randomised: PHT = 58, CBZ = 59
52 participants (44%) with partial epilepsy. 61 (52%) men
Age range: 4 to 75 years. Duration of treatment (range in months): 3 to 47
Interventions Monotherapy with PHT or CBZ
Mean daily dose achieved: PHT = 5.4 mg/kg, CBZ = 10.9 mg/kg
Outcomes Seizure control:
excellent (complete freedom of seizures)
good (> 50% reduction in seizure frequency)
poor (< 50% reduction in seizure frequency or no response)
Side effects
Notes Outcomes chosen for this review were not reported. IPD not available
Funding: Grants provided by Labaz, Geigy, and Warner-Lambert.
Conflicts of interest: None stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation based on 2 Latin squares
without stratification. The first, second and
third preference of drug for the participant
appears to have been taken into account
in the process. Unclear if assignment was
completely random
Allocation concealment (selection bias) High risk An independent person (department secre-
tary) selected the “drug of first preference”
from randomisation list on a sequential ba-
sis. Allocation not adequately concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided
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Callaghan 1985 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported. Intention-to-treat
approach taken, all randomised partici-
pants analysed
Selective reporting (reporting bias) Low risk Primary outcomes (seizure control) and
secondary outcomes (side effects) reported
sufficiently
Other bias Low risk No other bias detected
Cereghino 1974
Methods Randomised, double-blind cross-over trial with three 21-day treatment periods and 2-
week washout period (regular medications used) conducted in a single centre in New-
castle, Indiana, United States
Three treatment arms: carbamazepine, phenytoin and phenobarbitone
Dates conducted: Not stated
Participants Institutionalised adults with uncontrolled seizures on current medication
Number randomised: PHT = 45, CBZ = 45
41 participants (91%) with partial epilepsy. 28 (62%) men. Age range: 18 to 51 years
Study duration 13 weeks (3 x 21-day treatment periods plus 2 x 2-week washout periods)
Interventions Monotherapy with PHT or CBZ
Daily dose: PHT = 300 mg/day, or CBZ = 1200 mg/day
Outcomes Behaviour outcomes
Adverse effects
Seizure frequency
Time to treatment withdrawal due to poor seizure control
Notes Outcomes chosen for this review were not reported due to cross-over design
Funding: Supported in part by an NIH research contract
Conflicts of interest: None stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation of groups from random
number tables (confirmed by author)
Allocation concealment (selection bias) Unclear risk No information provided
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Cereghino 1974 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal rates reported, no further in-
formation provided
Selective reporting (reporting bias) Low risk All efficacy and tolerability outcomes spec-
ified in the Methods sections reported well
in the Results section. No protocol avail-
able, outcomes for this review not available
due to trial cross-over design
Other bias High risk Cross-over design may not be appropriate
for monotherapy designs, likely carry-over
effects from 1 period to another, so the
comparison may not be entirely monother-
apy
Czapinski 1997
Methods 36-month randomised, comparative study
Four treatment arms: carbamazepine, sodium valproate, phenytoin, phenobarbitone
Dates conducted and country: Not stated (assumed conducted in Poland due to author
affiliations)
Participants Adults with newly-diagnosed epilepsy
Number randomised: CBZ = 30, PHT = 30
100% partial epilepsy, Age range: 18 to 40 years
Percentage men and range of follow-up not mentioned (outcome recorded at 3 years)
Interventions Monotherapy with PHT or CBZ
Starting doses CBZ = 400 mg/day, PHT = 200 mg/day. Dose achieved not stated
Outcomes Proportion achieving 24-month remission at 3 years and exclusions after randomisation
due to adverse effects or no efficacy
Notes Abstract only. Outcomes chosen for this review were not reported, IPD pledged but not
received
Funding: Not stated
Conflicts of interest: None stated
Risk of bias Risk of bias
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Czapinski 1997 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study randomised but no further informa-
tion provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ”Exclusion rates“ reported for all treatment
groups, no further information provided
Selective reporting (reporting bias) Unclear risk Noprotocol available, study available in ab-
stract format only. Outcomes for this re-
view not available
Other bias Low risk No other bias detected
De Silva 1996
Methods Randomised, parallel-group, open-label paediatric study conducted in 2 centres in the
United Kingdom
Trial conducted between 1981 and 1987
Four treatment arms: carbamazepine, sodium valproate, phenytoin, phenobarbitone
Participants Children with newly-diagnosed epilepsy (2 or more untreated partial or generalised
tonic-clonic seizures in the 12 months preceding the study)
Number randomised: CBZ = 54, PHT = 54
64 children (59%) with partial epilepsy. 59 (55%) boys. Mean age (range): 9 (3 to 16)
years
Range of follow-up: 3 to 88 (months)
Interventions Monotherapy with PHT or CBZ.Median daily dose achieved: PHT = 175mg/day, CBZ
= 400 mg/day
Outcomes Time to first seizure recurrence after start of therapy
Time to 12-month remission from all seizures
Adverse effects and withdrawals due to adverse events
Notes IPD provided for all randomised participants. All outcomes in this review calculated
from IPD
Funding: support provided by the Medical Research Council, the Health Promotion
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De Silva 1996 (Continued)
Trust, Ciba-Geigy, Parke-Davis, and Sanofi
Conflicts of interest: None stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list generated using per-
muted blocks of size 8 or 16 with stratifi-
cation for centre, seizure type and presence
of neurological signs
Allocation concealment (selection bias) Low risk Allocation concealed via 4 batches of con-
cealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unblinded; authors state masking of treat-
ment would not be “practicable or ethical”
and would “undermine compliance.” Un-
clear if lack of masking influenced outcome
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unblinded; authors state masking of treat-
ment would not be “practicable or ethical”
and would “undermine compliance.” Un-
clear if lack of masking influenced outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported, all randomised
participants analysed from IPD provided1
Selective reporting (reporting bias) Low risk All outcomes reported or calculated with
IPD provided1
Other bias Low risk No other bias detected
Forsythe 1991
Methods Single-centre, randomised, parallel-group trial.
Three treatment arms: carbamazepine, phenytoin, sodium valproate
Dates conducted and country: Not stated (assumed conducted in United Kingdom due
to author affiliations)
Participants Children with at least 3 newly-diagnosed generalised or partial seizures within a period
of 6 months
Number randomised: PHT = 20, CBZ = 23
No information on epilepsy type, sex or range of follow-up
Age range: 5 to 14 years. Study duration: 12 months
Interventions Monotherapy with PHT or CBZ
Mean dose: PHT = 6.1 mg/day, CBZ = 17.9 mg/day
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Forsythe 1991 (Continued)
Outcomes Cognitive assessments
Summary of withdrawals from randomised drug
Notes Outcomes chosen for this review were not reported
IPD not available, but could be constructed from the publication for the outcome ’Time
to withdrawal of allocated drug’
Funding: A grant was obtained from the Yorkshire Regional Health Authority, support
for measuring serum levels provided by Ciba-Geigy PLC and Sanofi PLC
Conflicts of interest: None stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quota allocation by sex, age, seizure type
and current treatment is an inadequate ran-
domisation method
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Personnel and participants (and parents)
unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors single-blinded for cog-
nitive testing
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported, results reported
and analysed for all participants ran-
domised and all who completed various
stages of follow-up
Selective reporting (reporting bias) Unclear risk 1 of 4 outcomes for this review reported.
Cognitive outcomes described in Methods
sectionwell reported inResults section. Ad-
verse effects reported, no seizure outcomes
reported and outcomes chosen for this re-
view not reported. No protocol available so
unclear if seizure outcomes were planned a
priori
Other bias Low risk No other bias detected
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Heller 1995
Methods Randomised, parallel-group, open-label paediatric study conducted in 2 centres in the
United Kingdom
Trial conducted between 1981 and 1987
Four treatment arms: carbamazepine, sodium valproate, phenytoin, phenobarbitone
Participants Adults with newly-diagnosed epilepsy (2 or more untreated partial or generalised tonic-
clonic seizures in the 12 months preceding the study)
Number randomised: CBZ = 61, PHT = 63
52 participants (42%) with partial epilepsy. 64 (52%) men. Mean age (range): 31 (13
to 72) years
Range of follow-up (months): 1 to 91
Interventions Monotherapy with PHT or CBZ.Median daily dose achieved: PHT = 300mg/day, CBZ
= 600 mg/day
Outcomes Time to first seizure recurrence after start of therapy
Time to 12-month remission from all seizures
Adverse effects and withdrawals due to adverse events
Notes IPD provided for all randomised participants. All outcomes in this review calculated
from IPD
Funding: support provided by the Medical Research Council, the Health Promotion
Trust, Ciba-Geigy, Parke-Davis, and Sanofi
Conflicts of interest: None stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list generated using per-
muted blocks of size 8 or 16 with stratifi-
cation for centre, seizure type and presence
of neurological signs
Allocation concealment (selection bias) Low risk Allocation concealed via 4 batches of con-
cealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unblinded; authors state masking of treat-
ment would not be “practical” and would
have “introduced bias due to a very large
drop-out rate.” Unclear if outcome was in-
fluenced
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unblinded; authors state masking of treat-
ment would not be “practical” and would
have “introduced bias due to a very large
drop-out rate.” Unclear if outcome was in-
fluenced
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Heller 1995 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported, all randomised
participants analysed from IPD provided1
Selective reporting (reporting bias) Low risk All outcomes reported or calculated with
IPD provided1
Other bias Low risk No other bias detected
Mattson 1985
Methods Multicentre, randomised, parallel-group, double-blinded study over 10 centres in the
USA with separate randomisation schemes used for each seizure type
Four treatment arms: carbamazepine, phenytoin, phenobarbitone, primidone
Dates conducted: Not stated
Participants Adults with previously untreated or under-treated simple or complex partial or secondary
generalised tonic-clonic seizures
Number randomised: PHT = 165, CBZ = 155
100% partial epilepsy. 278 (87%) men. Mean age (range): 41 (18 to 82) years
Range of follow-up: 0 to 66 months
Interventions Monotherapy with PHT or CBZ.Median daily dose achieved: PHT = 400mg/day, CBZ
= 800 mg/day
Outcomes Participant retention/time to drug failure (length of time participant continued to take
randomised drug)
Composite scores of seizure frequency (seizure rates and total seizure control) and toxicity
Incidence of side effects
Notes IPD provided for all randomised participants. All outcomes in this review calculated
from IPD
Funding: supported by the Veterans Adminstration Medical Research Service Coopera-
tive Studies Program (CS 118)
Conflicts of interest: None stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants randomised with stratification
for seizure type. Method of randomisation
not stated and not provided by authors
Allocation concealment (selection bias) Unclear risk No information provided in the publica-
tion or by study authors
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Mattson 1985 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind (participants and personnel)
achieved using an additional blank tablet
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if outcome assessment was
blinded, no information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rates reported, all randomised
participants analysed from IPD provided1
Selective reporting (reporting bias) Low risk All outcomes reported or calculated with
IPD provided1
Other bias Low risk No other bias detected
Miura 1993
Methods Prospective randomised study.
Three treatment arms: carbamazepine, phenytoin and sodium valproate
Dates conducted and country: Not stated (assumed conducted in Japan due to author
affiliation)
Participants Children aged 1 to 14 with previously untreated partial seizures and/or generalised tonic-
clonic seizures
Number randomised: PHT = 51, CBZ = 66. 84 (72%) with partial seizures. No infor-
mation on gender
Range of follow-up: 6 to 66 months, mean follow-up: 37 months in PHT group, 34 in
CBZ group
Interventions Monotherapy with PHT or CBZ. Initial daily dose: PHT = 7.2 ± 1.4 mg/kg/day, CBZ
= 13.0 ± 1.6 mg/kg/day
Outcomes Proportion of all randomised participants with seizure recurrence (by seizure type)
Proportionof participantswith optimumplasma levelswith seizure recurrence (by seizure
type)
Notes Very limited information available.The study is reported in a summary publication of 3
different studies (other 2 studies are not CBZ vs PHT). Outcomes chosen for this review
were not reported, and IPD not available
Funding: Not stated
Conflicts of interest: None stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Miura 1993 (Continued)
Random sequence generation (selection
bias)
Unclear risk Study is described as ”randomised“ but no
further details are provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided; unclear if the
study was blinded or not
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided; unclear if the
study was blinded or not
Incomplete outcome data (attrition bias)
All outcomes
Low risk Ranges of follow-up given for both treat-
ment groups. Results reported ”at the end
of follow up,“ no withdrawals or exclu-
sions mentioned, all participants included
in analysis
Selective reporting (reporting bias) Unclear risk Seizure recurrence outcomes described and
well reported. No adverse events reported;
no protocol available so unclear if adverse
events were planned a priori. Outcomes for
this review not available
Other bias Low risk No other bias detected
Ogunrin 2005
Methods Double-blinded, parallel-group, randomised study conducted in a single centre inNigeria
between October 2000 and October 2002
Three treatment arms: carbamazepine, phenytoin, phenobarbitone
Participants Consecutive newly-diagnosed people aged 14 or over presenting at the outpatient neu-
rology clinic of the University Teaching Hopsital, Benin City, Nigeria with recurrent,
untreated afebrile seizures
Number randomised: PHT = 19, CBZ = 19
8 participants with partial seizures (22%), 23 men (62%). Mean age (range): 29.8 years
(14 to 38 years)
All participants followed up for 12 weeks
Interventions Monotherapy with PHT or CBZ. Median daily dose (range): PHT = 200 mg (100 to
300 mg), CBZ = 600 mg (400 to 1200 mg)
Outcomes Cognitive measures (reaction times, mental speed, memory, attention)
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Ogunrin 2005 (Continued)
Notes IPD provided for all randomised participants. Study duration was 12 weeks; all partic-
ipants completed the study without withdrawing, so outcomes ’Time to withdrawal of
allocated drug’, ’Time to six-month remission’ and ’Time to 12-month remission’ could
not be calculated. ’Time to first seizure’ calculated from IPD provided
Funding: Not stated
Conflicts of interest: None stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study randomised using simple randomi-
sation. Each participant was asked to pick 1
from a table of numbers (1 - 60), numbers
corresponded to allocation of 1 of 3 drugs
(information provided by author)
Allocation concealment (selection bias) Low risk Recruitment/randomisation
of participants and allocation of treatments
took place on different sites (information
provided by author)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants single-blinded. Research assis-
tant recruiting participants and counselling
on medication adherence was not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators performing cognitive assess-
ments were single-blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants completed the
study. All randomised participants analysed
from IPD provided1
Selective reporting (reporting bias) Low risk 1 outcome for this review calculated from
IPDprovided1 . Other outcomes for this re-
viewnot available due to short study length.
All cognitive outcomes from the study well
reported
Other bias Low risk No other bias detected
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Pulliainen 1994
Methods Single-centre, randomised, parallel-group trial of participants, referrals to the outpatient
department of neurology of the Central Hospital of Paijat-Hame, Finland
Two treatment arms: carbamazepine and phenytoin
Dates conducted: Not stated
Participants Adults (eligible age range 15 to 57) with newly-diagnosed epilepsy
Number randomised: PHT = 20, CBZ = 23*
10 (23%) participants with partial epilepsy. 20 (47%) men
Mean age (SD) years: PHT = 31.5 (11.3), CBZ = 26.8 (13.2)
Interventions Monotherapy with PHT or CBZ. Dose information not reported
Outcomes Cognitive assessments (visual motor speed, co-ordination, attention and concentration,
verbal and visuospatial learning, visual and recognition memory, reasoning, mood, hand-
edness)
Harmful side effects
Notes *59 participants were randomised but 16 were subsequently excluded. Results were
presented only for the 43 participants who completed the entire study
Outcomes chosen for this review were not reported. IPD not available
Funding: Not stated
Conflicts of interest: None stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomly assigned to
treatment groups, method of randomisa-
tion not stated
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided; unclear if par-
ticipants and personnel were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Cognitive outcome assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 16/59 (27%) of participants excluded from
analysis. Results presented only for 43 par-
ticipants who completed the study
Selective reporting (reporting bias) Unclear risk Cognitive outcomes described in Methods
sectionwell reported inResults section. Ad-
verse effects reported, no seizure outcomes
reported and outcomes chosen for this re-
view not reported. No protocol available so
56Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pulliainen 1994 (Continued)
unclear if seizure outcomes were planned a
priori
Other bias Low risk No other bias detected
Ramsay 1983
Methods Randomised, ’two compartment’ parallel study, conducted in the United States
Two treatment arms: carbamazepine and phenytoin
Dates conducted: Not stated
Participants Adults, previously untreated, with at least 2 seizures or at least 1 seizure and an EEG
with paroxysmal features
Number randomised: PHT = 45, CBZ = 42
55 participants (63%) with partial epilepsy. 60 (69%) men. Overall mean age (range)
37.4 (18 to 77) years
Study duration: 2 years. Range of follow-up not reported
Interventions Monotherapy with PHT or CBZ
Mean daily dose achieved (for the 54 participants with no major side effects): PHT = 5.
35 mg/kg/day, CBZ = 9.32 mg/kg/day
Outcomes Laboratory measures
Side effects (major and minor)
Seizure control/treatment failure
Notes 7 participants on CBZ and 10 participants on PHT were “dropped for non-compliance”
and excluded from analysis
Outcomes chosen for this review were not reported. IPD not available
Funding: Supported in part by the Southern Foundation for Brain Research
Conflicts of interest: None stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants randomly assigned to treat-
ment groups;methodof randomisationnot
stated
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind (participants and personnel)
achieved with additional blank tablet
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear if outcome assessors were blinded
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Ramsay 1983 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 17/87 (19.5%) of participants excluded
from analysis for ”non-compliance“. Re-
sults presented only for participants who
completed the study
Selective reporting (reporting bias) Low risk All efficacy and tolerability outcomes spec-
ified in the Methods sections reported well
in the Results section. No protocol avail-
able. Outcomes chosen for this review were
not reported
Other bias Unclear risk No other bias detected
Ravi Sudhir 1995
Methods Single-centre, randomised, parallel-group study of participants referred to theNeurology
Clinic of Nehru Hospital, Chandigarh, India
Two treatment arms: carbamazepine and phenytoin
Dates conducted: Not stated
Participants Newly-diagnosed and drug naïve adults over the age of 14 attending the Neurology
Clinic of Nehru Hospital, Chandigarh, India
Number randomised: PHT = 20, CBZ = 20
11 participants with partial epilepsy (27.5%), 28 men (70%)
Mean age (range): PHT group 23.4 (14 to 44 years), CBZ 24.4 (14 to 45 years)
Study duration 10 to 12 weeks. Range of follow-up not reported
Interventions Monotherapy with PHT or CBZ. Initial daily dose: PHT = 5 mg/kg/day, CBZ = 10 mg/
kg/day
Outcomes Cognitive measures before and after treatments (verbal, performance, memory, visuo-
motor, perceptomotor organisation, visual organisation, dysfunction)
Notes 6 participants on CBZ and 8 participants on PHT were excluded from final analysis of
cognitive assessments who were lost to follow-up or who had uncontrolled seizures
Outcomes chosen for this review were not reported. IPD not available
Funding: Not stated
Conflicts of interest: None stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”The subjects were randomised to one of
the two study groups,“ no further informa-
tion given on methods of randomisation
Allocation concealment (selection bias) Unclear risk No information provided
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Ravi Sudhir 1995 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information provided; unclear if study
was blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided; unclear if study
was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 14/40 (35%) of participants excluded from
analysis who were lost to follow-up or expe-
rienced uncontrolled seizures. Results pre-
sented only for participants who completed
the study
Selective reporting (reporting bias) Unclear risk Cognitive outcomes described in Methods
section well reported in Results section. No
seizure outcomes or adverse events reported
and outcomes chosen for this review not
reported. No protocol available, so unclear
if seizure outcomes were planned a priori
Other bias Low risk No other bias detected
1For studies in which IPD were provided (De Silva 1996; Heller 1995; Mattson 1985; Ogunrin 2005) attrition and reporting bias are
reduced as attrition rates and unpublished outcome data are requested.
CBZ: carbamazepine
EEG: electroencephalograph
IPD: individual participant data
PHT: phenytoin
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bird 1966 Unclear whether trial is randomised and unclear whether participants received either CBZ or PHT as
monotherapy. Authors could not be contacted to clarify therefore trial excluded due to uncertainties
Bittencourt 1993 Comparison between CBZ monotherapy and PHT monotherapy cannot be made. Participants were given
phenobarbital initially which was later withdrawn whilst either CBZ or PHT was also introduced
Canadian Study 1998 Comparison between CBZ monotherapy and PHT monotherapy cannot be made. No randomised
monotherapy comparison between CBZ and PHT. Participants were separated into 2 treatment arms (based
on previous drug failure) and randomised to CBZ and clobazam in 1 arm and PHT or clobazam in the other
arm
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(Continued)
Hakami 2012 Comparison between CBZ monotherapy and PHT monotherapy cannot be made. Participants who failed
CBZ or PHT monotherapy were randomised to levetiracetam or VPS monotherapy
Kaminow 2003 Participants were randomised to lamotrigine or ’standard therapy’ (PHT, CBZ or VPA at the choice of the
investigator). No randomised comparison can be made of CBZ and PHT
Kosteljanetz 1979 Comparison between CBZ monotherapy and PHT monotherapy cannot be made. All medication except
phenobarbital and primidone were discontinued gradually, whilst dose of randomised drug CBZ or PHT
was increased
Kuzuya 1993 Study is not randomised; participants were already on CBZ or PHT monotherapy on entry into the study
Rajotte 1967 Unclear if the study was randomised. Comparison between CBZ monotherapy and PHT monotherapy
cannot be made. The trial has a cross-over design with a 2-week washout period in which both drugs were
taken to make a gradual transition
Sabers 1995 Not fully randomised: “The treatment was chosen at random unless the individual diagnoses required a
specific drug”
Shakir 1980 Direct comparison between CBZ and PHT not available. The publication reports 2 separate randomised
studies, the first compares VPS and PHT and the second compares VPS and CBZ
Shorvon 1978 Study is not randomised
Simonsen 1976 Randomised participants were slowly withdrawn from their previous treatment as part of the trial and
therefore a comparison between CBZ and PHT monotherapy cannot be made
Troupin 1975 All participants received PHT for 2 months prior to entering a randomised cross-over period. It is unclear
whether a comparison between CBZ and PHT monotherapy could be made
Zeng 2010 The study is not randomised - the investigator made the choice of treatment for each participant
CBZ: carbamazepine
PHT: phenytoin
VPS: sodium valproate
Characteristics of studies awaiting assessment [ordered by study ID]
Rysz 1994
Methods 2-arm trial of carbamazepine and phenytoin. Unclear from information provided in the abstract if the study is
randomised
Participants 64 participants with untreated partial (n = 9), partial complex (n = 27), partial secondary generalised (n = 22), or
primary generalised seizures (n = 6)
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Rysz 1994 (Continued)
Interventions Monotherapy with carbamazepine or phenytoin. Unclear how many participants were allocated to each drug
Outcomes Somatosensoric evoked potentials (mean wave amplitude, mean proximal conduction time, mean central conduction
time)
Notes Full-text available only in Polish; abstract available in English. Full-text is awaiting translation before eligibility can
be judged
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D A T A A N D A N A L Y S E S
Comparison 1. Carbamazepine versus phenytoin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to withdrawal of allocated
treatment
4 589 Hazard Ratio (Fixed, 95% CI) 0.99 [0.75, 1.30]
2 Time to withdrawal of allocated
treatment - stratified by
epilepsy type
3 546 Hazard Ratio (Fixed, 95% CI) 1.04 [0.78, 1.39]
2.1 Partial onset 3 428 Hazard Ratio (Fixed, 95% CI) 1.18 [0.87, 1.60]
2.2 Generalised seizures 2 118 Hazard Ratio (Fixed, 95% CI) 0.42 [0.18, 0.96]
3 Time to achieve 12-month
remission
3 551 Hazard Ratio (Fixed, 95% CI) 0.99 [0.79, 1.25]
4 Time to achieve 12-month
remission - stratified by
epilepsy type
3 551 Hazard Ratio (Random, 95% CI) 1.01 [0.78, 1.31]
4.1 Partial onset 3 430 Hazard Ratio (Random, 95% CI) 0.94 [0.71, 1.25]
4.2 Generalised seizures 2 121 Hazard Ratio (Random, 95% CI) 1.17 [0.53, 2.57]
5 Time to achieve six-month
remission
3 551 Hazard Ratio (Fixed, 95% CI) 1.08 [0.87, 1.34]
6 Time to achieve six-month
remission - stratified by
epilepsy type
3 551 Hazard Ratio (Fixed, 95% CI) 1.11 [0.89, 1.37]
6.1 Partial onset 3 430 Hazard Ratio (Fixed, 95% CI) 1.02 [0.79, 1.33]
6.2 Generalised seizures 2 121 Hazard Ratio (Fixed, 95% CI) 1.30 [0.89, 1.92]
7 Time to first seizure
post-randomisation
4 582 Hazard Ratio (Fixed, 95% CI) 0.88 [0.72, 1.08]
8 Time to first seizure
post-randomisation - stratified
by epilepsy type
4 582 Hazard Ratio (Fixed, 95% CI) 0.85 [0.70, 1.04]
8.1 Partial onset 4 432 Hazard Ratio (Fixed, 95% CI) 0.86 [0.68, 1.08]
8.2 Generalised onset 3 150 Hazard Ratio (Fixed, 95% CI) 0.84 [0.57, 1.24]
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Analysis 1.1. Comparison 1 Carbamazepine versus phenytoin, Outcome 1 Time to withdrawal of allocated
treatment.
Review: Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenytoin
Outcome: 1 Time to withdrawal of allocated treatment
Study or subgroup Phenytoin Carbamazepine log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
De Silva 1996 53 53 -0.09254 (0.32917) 17.9 % 0.91 [ 0.48, 1.74 ]
Forsythe 1991 20 23 -0.36895 (0.52732) 7.0 % 0.69 [ 0.25, 1.94 ]
Heller 1995 61 60 -0.45985 (0.37854) 13.6 % 0.63 [ 0.30, 1.33 ]
Mattson 1985 165 154 0.14791 (0.17766) 61.5 % 1.16 [ 0.82, 1.64 ]
Total (95% CI) 299 290 100.0 % 0.99 [ 0.75, 1.30 ]
Heterogeneity: Chi2 = 2.73, df = 3 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PHT Favours CBZ
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Analysis 1.2. Comparison 1 Carbamazepine versus phenytoin, Outcome 2 Time to withdrawal of allocated
treatment - stratified by epilepsy type.
Review: Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenytoin
Outcome: 2 Time to withdrawal of allocated treatment - stratified by epilepsy type
Study or subgroup Phenytoin Carbamazepine log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Partial onset
De Silva 1996 30 28 0.26349 (0.42816) 11.7 % 1.30 [ 0.56, 3.01 ]
Heller 1995 27 24 0.13268 (0.50548) 8.4 % 1.14 [ 0.42, 3.08 ]
Mattson 1985 165 154 0.14791 (0.17766) 68.0 % 1.16 [ 0.82, 1.64 ]
Subtotal (95% CI) 222 206 88.1 % 1.18 [ 0.87, 1.60 ]
Heterogeneity: Chi2 = 0.07, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
2 Generalised seizures
De Silva 1996 23 25 -0.59522 (0.54909) 7.1 % 0.55 [ 0.19, 1.62 ]
Heller 1995 34 36 -1.27062 (0.66845) 4.8 % 0.28 [ 0.08, 1.04 ]
Subtotal (95% CI) 57 61 11.9 % 0.42 [ 0.18, 0.96 ]
Heterogeneity: Chi2 = 0.61, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 2.04 (P = 0.041)
Total (95% CI) 279 267 100.0 % 1.04 [ 0.78, 1.39 ]
Heterogeneity: Chi2 = 5.86, df = 4 (P = 0.21); I2 =32%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Chi2 = 5.18, df = 1 (P = 0.02), I2 =81%
0.01 0.1 1 10 100
Favours PHT Favours CBZ
64Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.3. Comparison 1 Carbamazepine versus phenytoin, Outcome 3 Time to achieve 12-month
remission.
Review: Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenytoin
Outcome: 3 Time to achieve 12-month remission
Study or subgroup Phenytoin Carbamazepine log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
De Silva 1996 54 54 0.20155 (0.20884) 32.3 % 1.22 [ 0.81, 1.84 ]
Heller 1995 63 61 -0.09483 (0.21657) 30.1 % 0.91 [ 0.59, 1.39 ]
Mattson 1985 165 154 -0.11857 (0.19378) 37.6 % 0.89 [ 0.61, 1.30 ]
Total (95% CI) 282 269 100.0 % 0.99 [ 0.79, 1.25 ]
Heterogeneity: Chi2 = 1.49, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours CBZ Favours PHT
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Analysis 1.4. Comparison 1 Carbamazepine versus phenytoin, Outcome 4 Time to achieve 12-month
remission - stratified by epilepsy type.
Review: Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenytoin
Outcome: 4 Time to achieve 12-month remission - stratified by epilepsy type
Study or subgroup Phenytoin Carbamazepine log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Partial onset
De Silva 1996 30 29 -0.097 (0.29098) 18.0 % 0.91 [ 0.51, 1.61 ]
Heller 1995 28 24 0.17948 (0.35009) 13.0 % 1.20 [ 0.60, 2.38 ]
Mattson 1985 165 154 -0.11857 (0.19378) 34.3 % 0.89 [ 0.61, 1.30 ]
Subtotal (95% CI) 223 207 65.4 % 0.94 [ 0.71, 1.25 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 2 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
2 Generalised seizures
De Silva 1996 24 25 0.56595 (0.31133) 16.0 % 1.76 [ 0.96, 3.24 ]
Heller 1995 35 37 -0.23967 (0.28543) 18.6 % 0.79 [ 0.45, 1.38 ]
Subtotal (95% CI) 59 62 34.6 % 1.17 [ 0.53, 2.57 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 3.64, df = 1 (P = 0.06); I2 =73%
Test for overall effect: Z = 0.38 (P = 0.70)
Total (95% CI) 282 269 100.0 % 1.01 [ 0.78, 1.31 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.76, df = 4 (P = 0.31); I2 =16%
Test for overall effect: Z = 0.08 (P = 0.93)
Test for subgroup differences: Chi2 = 0.25, df = 1 (P = 0.62), I2 =0.0%
0.01 0.1 1 10 100
Favours CBZ Favours PHT
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Analysis 1.5. Comparison 1 Carbamazepine versus phenytoin, Outcome 5 Time to achieve six-month
remission.
Review: Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenytoin
Outcome: 5 Time to achieve six-month remission
Study or subgroup Phenytoin Carbamazepine log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
De Silva 1996 54 54 0.12899 (0.20624) 28.2 % 1.14 [ 0.76, 1.70 ]
Heller 1995 63 61 -0.01768 (0.19948) 30.2 % 0.98 [ 0.66, 1.45 ]
Mattson 1985 165 154 0.11929 (0.16975) 41.6 % 1.13 [ 0.81, 1.57 ]
Total (95% CI) 282 269 100.0 % 1.08 [ 0.87, 1.34 ]
Heterogeneity: Chi2 = 0.35, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours CBZ Favours PHT
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Analysis 1.6. Comparison 1 Carbamazepine versus phenytoin, Outcome 6 Time to achieve six-month
remission - stratified by epilepsy type.
Review: Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenytoin
Outcome: 6 Time to achieve six-month remission - stratified by epilepsy type
Study or subgroup Phenytoin Carbamazepine log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Partial onset
De Silva 1996 30 29 -0.21795 (0.28725) 14.7 % 0.80 [ 0.46, 1.41 ]
Heller 1995 28 24 -0.01072 (0.3205) 11.8 % 0.99 [ 0.53, 1.85 ]
Mattson 1985 165 154 0.11929 (0.16975) 42.1 % 1.13 [ 0.81, 1.57 ]
Subtotal (95% CI) 223 207 68.6 % 1.02 [ 0.79, 1.33 ]
Heterogeneity: Chi2 = 1.04, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
2 Generalised seizures
De Silva 1996 24 25 0.5671 (0.3061) 12.9 % 1.76 [ 0.97, 3.21 ]
Heller 1995 35 37 0.05533 (0.25592) 18.5 % 1.06 [ 0.64, 1.75 ]
Subtotal (95% CI) 59 62 31.4 % 1.30 [ 0.89, 1.92 ]
Heterogeneity: Chi2 = 1.65, df = 1 (P = 0.20); I2 =39%
Test for overall effect: Z = 1.35 (P = 0.18)
Total (95% CI) 282 269 100.0 % 1.11 [ 0.89, 1.37 ]
Heterogeneity: Chi2 = 3.72, df = 4 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 1.03, df = 1 (P = 0.31), I2 =3%
0.01 0.1 1 10 100
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Analysis 1.7. Comparison 1 Carbamazepine versus phenytoin, Outcome 7 Time to first seizure post-
randomisation.
Review: Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenytoin
Outcome: 7 Time to first seizure post-randomisation
Study or subgroup Phenytoin Carbamazepine log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
De Silva 1996 54 54 -0.36392 (0.20537) 25.3 % 0.69 [ 0.46, 1.04 ]
Heller 1995 63 61 0.10556 (0.20696) 24.9 % 1.11 [ 0.74, 1.67 ]
Mattson 1985 162 151 -0.05 (0.15392) 45.0 % 0.95 [ 0.70, 1.29 ]
Ogunrin 2005 18 19 -0.73609 (0.46929) 4.8 % 0.48 [ 0.19, 1.20 ]
Total (95% CI) 297 285 100.0 % 0.88 [ 0.72, 1.08 ]
Heterogeneity: Chi2 = 4.53, df = 3 (P = 0.21); I2 =34%
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PHT Favours CBZ
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Analysis 1.8. Comparison 1 Carbamazepine versus phenytoin, Outcome 8 Time to first seizure post-
randomisation - stratified by epilepsy type.
Review: Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review
Comparison: 1 Carbamazepine versus phenytoin
Outcome: 8 Time to first seizure post-randomisation - stratified by epilepsy type
Study or subgroup Phenytoin Carbamazepine log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Partial onset
De Silva 1996 30 29 -0.29341 (0.27344) 13.8 % 0.75 [ 0.44, 1.27 ]
Heller 1995 28 24 -0.13002 (0.30041) 11.4 % 0.88 [ 0.49, 1.58 ]
Mattson 1985 162 151 -0.05 (0.15392) 43.5 % 0.95 [ 0.70, 1.29 ]
Ogunrin 2005 3 5 -0.73609 (0.46929) 4.7 % 0.48 [ 0.19, 1.20 ]
Subtotal (95% CI) 223 209 73.4 % 0.86 [ 0.68, 1.08 ]
Heterogeneity: Chi2 = 2.26, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
2 Generalised onset
De Silva 1996 24 25 -0.46566 (0.31338) 10.5 % 0.63 [ 0.34, 1.16 ]
Heller 1995 35 37 0.22736 (0.28994) 12.3 % 1.26 [ 0.71, 2.22 ]
Ogunrin 2005 15 14 -0.65715 (0.52266) 3.8 % 0.52 [ 0.19, 1.44 ]
Subtotal (95% CI) 74 76 26.6 % 0.84 [ 0.57, 1.24 ]
Heterogeneity: Chi2 = 3.64, df = 2 (P = 0.16); I2 =45%
Test for overall effect: Z = 0.88 (P = 0.38)
Total (95% CI) 297 285 100.0 % 0.85 [ 0.70, 1.04 ]
Heterogeneity: Chi2 = 5.91, df = 6 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
0.01 0.1 1 10 100
Favours PHT Favours CBZ
A D D I T I O N A L T A B L E S
Table 1. Outcomes considered and summary of results for trials with no IPD
Trial Outcomes reported Summary of results
Callaghan 1985 1. Seizure control:
excellent (seizure-free)
good (> 50% reduction)
poor (< 50% reduction)
1. PHT (n = 58); CBZ (n = 59)
PHT: 39 (67%); CBZ: 22 (37%)
PHT: 7 (12%); CBZ: 22 (37%)
PHT: 12 (21%); CBZ: 15 (25%)
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Table 1. Outcomes considered and summary of results for trials with no IPD (Continued)
2. Side effects PHT: 6 (10%); CBZ: 5 (8%)
Cereghino 1974 1. Behaviour measured with rating scale modified from
the Ward Behaviour Rating Scale
2. Seizure control
3. Side effects
4. Withdrawals
1. Behavioural scores were similar on both drugs
2. No difference between CBZ and PHT in terms of
seizure control
3. Gastrointestinal and “impaired function” side effects
were more common on CBZ than PHT in the first few
study days. Side effects of both drugs were minimal in
later stages of the study
4. PHT: 21 withdrawals out of 45 participants (47%)
; CBZ: 27 withdrawals out of 45 participants (60%)
Czapinski 1997 1. Proportion achieving 24-month remission at 3 years
2. Proportion excluded after randomisation due to ad-
verse effects or no efficacy
1. PHT: 59%; CBZ: 62%
2. PHT: 23%; CBZ: 30%
Forsythe 1991 1. Cognitive assessments
2. Withdrawals from randomised drug
1.No significant differences between the two treatment
groups on any cognitive tests
2. PHT: 6 withdrawals out of 20 participants (30%);
CBZ: 9 withdrawals out of 23 participants (39%)
Miura 1993 1. Proportion of all randomised participants with
seizure recurrence (by seizure type)
2. Proportion of participants with optimum plasma
levels with seizure recurrence (by seizure type)
PHT (n = 51); CBZ (n = 66)
1. PHT (partial): 10/31 (32%); PHT (generalised): 7/
20 (35%);
CBZ (partial): 21/53 (40%); CBZ (generalised): 2/13
(15%)
2. PHT (partial): 4/17 (24%); PHT (generalised): 1/8
(13%);
CBZ (partial): 4/17 (24%); CBZ (generalised): 0/7
(0%)
Pulliainen 1994 1. Cognitive assessments (visual motor speed, co-ordi-
nation, attention and concentration, verbal and visu-
ospatial learning, visual and recognition memory, rea-
soning, mood, handedness)
2. Harmful side effects
1. Compared to CBZ, participants on PHT became
slower (motor speed of the hand) and their visualmem-
ory decreased. There was an equal decrease in negative
mood (helplessness, irritability, depression) on PHT
and CBZ
2. Three participants taking PHT complained of tired-
ness, and 1 participant taking CBZ complained of
facial skin problems, another tiredness and memory
problems
Ramsay 1983 1. Side effects (major and minor)
2. Treatment failure/seizure control
3. Laboratory results
1. Incidence of:
• major side effects (among analysed participants):
PHT 8/35 participants (23%); CBZ 8/35
participants (23%)
• minor side effects: cognitive impairment and
sedation twice as likely on CBZ as PHT
• other minor side effects similar between groups
2. Treatment failures among analysed participants:
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Table 1. Outcomes considered and summary of results for trials with no IPD (Continued)
PHT 4/35 (11%); CBZ: 5/35 (14%)
Seizure control (among analysed participants with no
major side effects): PHT: 23/27 participants (86%);
CBZ: 22/27 participants (82%)
3. Significantly lower mean LDH level at 24 weeks
in CBZ participants than PHT participants (P < 0.
01). Other laboratory results similar across treatment
groups
Ravi Sudhir 1995 1. Cognitive measures (verbal, performance, memory,
visuomotor, perceptomotor organisation, visual organ-
isation, dysfunction)
1. No significant differences between any tests of cog-
nitive function taken before treatment and after 10 -
12 weeks for both treatment groups
CBZ = carbamazepine, LDH = lactate dehydrogenase, PHT= phenytoin
Table 2. Number of participants contributing to each analysis
Trial Number randomised Time to withdrawal
of
allocated treatment
Time to 12-month
remission
Time to 6-month re-
mission
Time to first seizure
PHT CBZ Total PHT CBZ Total PHT CBZ Total PHT CBZ Total PHT CBZ Total
De
Silva
1996
1
54 54 108 53 53 106 54 54 108 54 54 108 54 54 108
Heller
1995
2
63 61 124 61 60 121 63 61 124 63 61 124 63 61 124
Matt-
son
1985
3
165 155 320 165 154 319 165 154 319 165 154 319 162 151 313
Forsythe
1991
4
20 23 43 20 23 43 Information not avail-
able
Information not
available
Information not avail-
able
Ogun-
rin
2005
5
18 19 37 Information not avail-
able
Information not avail-
able
Information not
available
18 19 37
Total 320 312 632 299 290 589 282 269 551 282 269 551 297 285 582
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CBZ = carbamazepine, PHT= phenytoin
1Individual participant data (IPD) supplied for 114 participants recruited in De Silva 1996; randomised drug not recorded in six
participants. Reasons for treatment withdrawal not available for two participants (one randomised to CBZ and one to PHT); these
participants are not included in analysis of Time to treatment withdrawal.
2Reasons for treatment withdrawal not available for three participants (one randomised to CBZ and two to PHT) in Heller 1995; these
participants are not included in analysis of Time to treatment withdrawal.
3No follow-up data after randomisation available for one participant randomised to CBZ in Mattson 1985. Data on seizure recurrence
not available for six additional participants (three randomised to CBZ and three to PHT); these participants are not included in the
analysis of Time to first seizure.
4IPD for Time to treatment withdrawal available in the study publication of Forsythe 1991. Data for other outcomes not available.
5Study duration of Ogunrin 2005 is 12 weeks, so six- and 12-month remission of seizures could not be achieved and cannot therefore
be calculated. All randomised participants completed the study without withdrawing from treatment, so time to treatment withdrawal
cannot be analysed.
Table 3. Reasons for premature discontinuation (withdrawal of allocated treatment)
Reason
for early
termi-
nation
Classifi-
cation
De Silva 19962 Forsythe 1991 Heller 19952,3 Mattson 1985 Total1
CBZ
n = 53
PHT
n = 53
CBZ
n = 23
PHT
n = 20
CBZ
n = 60
PHT
n = 63
CBZ
n = 154
PHT
n = 165
CBZ
n = 290
PHT
n = 299
Adverse
events
Event 3 2 4 1 8 1 11 8 26 12
Seizure
recur-
rence
Event 12 10 2 1 5 8 3 6 22 25
Both
seizure
recur-
rence
and ad-
verse
events
Event 6 5 0 0 4 2 31 33 31 40
Non-
compli-
ance/
partici-
pant
choice
Event 0 0 3 4 0 0 11 26 14 30
Partici-
pant
went
into re-
mission
Cen-
sored
18 24 0 0 6 14 0 0 24 38
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Table 3. Reasons for premature discontinuation (withdrawal of allocated treatment) (Continued)
Lost to
follow-
up
Cen-
sored
0 0 0 0 0 0 26 19 26 19
Death4 Cen-
sored
0 0 0 0 0 0 4 5 4 5
Other5 Cen-
sored
0 0 0 0 0 0 16 11 16 11
Com-
pleted
the
study
(did not
with-
draw)
Cen-
sored
14 12 14 14 37 38 53 57 118 121
n = number of individuals contributing to the outcome ’Time to withdrawal of allocated treatment’
1All participants in Ogunrin 2005 completed the study without withdrawing, so this study did not contribute to ’Time to withdrawal
of allocated treatment’.
2One participant for Heller 1995 (CBZ) and two for De Silva 1996 (one PHT and one CBZ) have missing reasons for treatment
withdrawal.
3Two participants from Heller 1995 (both PHT) had missing withdrawal times and did not contribute to analysis, but reasons for
withdrawal are given.
4Death due to reasons not related to the study drug.
5Other reasons from Mattson 1985: participants developed other medical disorders including neurological and psychiatric disorders.
Table 4. Sensitivity analysis - Epilepsy type misclassification, fixed-effect analysis
Analysis Time to withdrawal Time to six-month
remission
Time to 12-month
remission*
Time to first seizure
Original analysis P: 1.18 (0.87, 1.60)
G: 0.42 (0.18, 0.96)
O: 1.04 (0.78, 1.39)
P: 1.02 (0.79, 1.33)
G: 1.30 (0.89, 1.92)
O: 1.11 (0.89, 1.37)
P: 0.94 (0.71, 1.25)
G: 1.17 (0.53, 2.57)
O: 1.01 (0.78, 1.31)
P: 0.86 (0.68, 1.08)
G: 0.84 (0.57, 1.24)
O: 0.85 (0.70, 1.04)
Test for interaction Chi2 = 5.18; df = 1
P = 0.02; I2 = 80.7%
Chi2 = 1.03; df = 1
P = 0.31; I2 = 3.4%
Chi2 = 0.25; df = 1
P = 0.62; I2 = 0%
Chi2 = 0.01; df = 1
P = 0.93; I2 = 0%
Generalised and age at
onset > 30
(classified as uncertain
epilepsy type)
P: 1.18 (0.87, 1.60)
G: 0.51 (0.21, 1.24)
U: 0.19 (0.02, 2.14)
O: 1.05 (0.79, 1.40)
P: 1.02 (0.79, 1.33)
G: 1.69 (1.07, 2.27)
U: 0.84 (0.35, 1.98)
O: 1.13 (0.91, 1.41)
P: 0.94 (0.71, 1.25)
G: 1.44 (0.90, 2.31)
U: 0.52 (0.20, 1.34)
O: 1.01 (0.80, 1.28)
P: 0.86 (0.68, 1.08)
G: 0.91 (0.57, 1.46)
U: 0.97 (0.43, 2.18)
O: 0.88 (0.72, 1.07)
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Table 4. Sensitivity analysis - Epilepsy type misclassification, fixed-effect analysis (Continued)
Test for interaction Chi2 = 4.99; df = 2
P = 0.08; I2 = 59.9%
Chi2 = 4.01; df = 2
P = 0.13; I2 = 50.2%
Chi2 = 4.32; df = 2
P = 0.12; I2 = 53.7%
Chi2 = 0.12; df = 2
P = 0.94; I2 = 0%
Generalised and age at
onset > 30
(reclassified as partial
epilepsy)
P: 1.11 (0.82, 1.50)
G: 0.51 (0.21, 1.24)
O: 1.02 (0.77, 1.36)
P: 1.02 (0.80, 1.31)
G: 1.69 (1.07, 2.27)
O: 1.15 (0.92, 1.42)
P: 0.91 (0.69, 1.19)
G: 1.44 (0.90, 2.31)
O: 1.02 (0.81, 1.29)
P: 0.86 (0.69, 1.08)
G: 0.91 (0.57, 1.46)
O: 0.87 (0.71, 1.07)
Test for interaction Chi2 = 2.65; df = 1
P = 0.10; I2 = 62.3%
Chi2 = 3.63; df = 1
P = 0.06; I2 = 72.5%
Chi2 = 2.79; df = 1
P = 0.09; I2 = 64.2%
Chi2 = 0.04; df = 1
P = 0.83; I2 = 0%
df = degrees of freedom of Chi² distribution, G = generalised epilepsy, O = overall (all participants), P = partial epilepsy, U = uncertain
seizure type
Results are presented as pooled hazard ratio (HR) (95% confidence interval (CI)) with fixed-effect.
P < 0.05 is classified as statistically significant.
29 participants fromHeller 1995 reclassified to partial epilepsy or uncertain epilepsy type for outcomes ’Time to treatment withdrawal’,
’Time to 12-month remission’ and ’Time to 6-month remission.’
48 participants from Heller 1995 and Ogunrin 2005 reclassified to partial epilepsy or uncertain epilepsy type for outcome ’Time to
first seizure.’
See Analysis 1.2; Analysis 1.4; Analysis 1.6; and Analysis 1.8 for original analyses of ’Time to treatment withdrawal’, ’Time to 12-
month remission’, ’Time to 6-month remission’ and ’Time to first seizure’, all stratified by epilepsy respectively.
* Original analysis calculated with random-effects model due to substantial heterogeneity (see Analysis 1.4). Sensitivity analyses
calculated with fixed-effect model as no heterogeneity is present following reclassification of 29 participants in Heller 1995.
Table 5. Adverse event data (narrative report)
Trial Adverse event data1 Summary of reported results
Carbamazepine (CBZ) Phenytoin (PHT)
Callaghan 19852 All adverse events according to drug
(note: noparticipantswithdrewdue
to adverse events)
CBZ (n = 59):
drowsiness (n = 2), rash (n = 3)
PHT (n = 58):
gum hypertrophy (n = 2), rash (n =
2), ataxia (n = 2)
Cereghino 19742,3 Most frequently observed side ef-
fects
Gastrointestinal side ef-
fects and “impaired function” (gen-
eral malaise). Frequency not clearly
stated
Gastrointestinal side ef-
fects and “impaired function” (gen-
eral malaise). Frequency not clearly
stated
Czapinski 19974 “Exclusions” due to adverse events
or no efficacy”
Proportion “excluded”:
CBZ: 30% (out of 30 randomised
to CBZ)
Proportion “excluded”:
PHT: 23.3% (out of 30 randomised
to PHT)
De Silva 1996 “Unacceptable” adverse events
leading to drug withdrawal5
CBZ (n = 54):
drowsiness (n = 1), blood dyscrasia
PHT (n = 54):
drowsiness (n = 2), skin rash (n = 1)
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Table 5. Adverse event data (narrative report) (Continued)
(n = 1) , blood dyscrasia (n = 1), hirsutism
(n = 1)
Forsythe 1991 Withdrawal due to adverse events
(no other adverse event data re-
ported)
4 participants out of 23 randomised
to CBZ withdrew for the following
reasons (some withdrew for more
than adverse event):
slow-
ing of mental function, headache,
anorexia, nausea, abdominal pain,
fatigue and drowsiness2
1 participant out of 20 randomised
to PHT withdrew from the study
due to depression and anorexia
Heller 1995 “Unacceptable” adverse events
leading to drug withdrawal5
CBZ (n = 61):
drowsiness (n = 3), rash (n = 2),
headache (n = 1), depression (n = 1)
PHT (n = 63):
myalgia (n = 1), irritability (n = 1)
Mattson 19852 Narrative report of ‘Adverse effects’
and ‘Serious side effects’
CBZ (n = 155):
motor disturbance (ataxia, incoor-
dination, nystagmus, tremor: 33%)
;
dysmorphic and idiosyncratic side
effects (gum hypertrophy, hir-
sutism, acne and rash: 14%);
gastrointestinal problems (27%);
decreased libido or impotence
(13%);
No serious side effects
PHT (n = 165);
motor disturbance (ataxia, incoor-
dination, nystagmus, tremor: 28%)
;
dysmorphic and idiosyncratic side
effects (gum hypertrophy, hir-
sutism, acne and rash: 22 %);
gastrointestinal problems (24%);
decreased libido or impotence
(11%)
1 serious side effect - 1 participant
has confirmed lymphoma, rash im-
proved rapidly following discontin-
uation of PHT
Miura 1993 No adverse events reported N/A N/A
Ogunrin 20052 Participant reported symptomatic
complaints (provided as IPD)
CBZ (n = 19):
memory impairment (n = 9)
psychomotor retardation (n = 1)
inattention (n = 1)
transient rash (n = 1)
CBZ-induced cough (n = 1)
PHT (n = 18):
memory impairment (n = 7)
psychomotor retardation (n = 1)
inattention (n = 2)
transient rash (n = 1)
Pulliainen 1994 Participant-reported adverse events 1 participant on CBZ complained
of facial skin problems;
1 participant on CBZ complained
of tiredness and memory problems
3 participants on PHT complained
of tiredness
Ramsay 19832 Major and minor side effects CBZ (n = 35):
Major side effects:
rash (n = 1), pruritus (n = 1), im-
potence (n = 2), dizziness (n = 1),
PHT (n = 35):
Major side effects:
rash (n = 4), exfoliative dermatitis
(n = 1), impotence (n = 1), dizziness
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Table 5. Adverse event data (narrative report) (Continued)
headaches (n = 1), impaired cogni-
tion (n = 1), elevated liver enzymes
(n = 1)
Mild side effects:
nausea (33%), headaches (24%),
cognitive impairment (33%), nys-
tagmus (52%), sedation (33%), fine
tremor (20%)
(n = 1), nausea/vomiting (n = 1)
Mild side effects:
nausea (38%), gingival hyperpla-
sia (12%), headaches (32%), cogni-
tive impairment (15%), nystagmus
(40%), sedation (15%), fine tremor
(28%)
Ravi Sudhir 1995 No adverse events reported N/A N/A
CBZ = carbamazepine, N/A = not available, PHT= phenytoin
1Adverse event data are recorded as reported narratively in the publications, so exact definition of a symptom may vary. Adverse event
data supplied as IPD for Ogunrin 2005. Adverse event data were not requested in original IPD requests (De Silva 1996; Heller 1995;
Mattson 1985) but will be for all future IPD requests. For numbers of withdrawals due to adverse events in studies for which IPD were
provided (De Silva 1996; Heller 1995; Mattson 1985) see Table 3.
2Participants may report more than one adverse event.
3Note that the recruited participants in Cereghino 1974 were institutionalised, so “precise nature of side effects was not always
determinable.” The two most frequently occurring side effects were reported as the frequency of participants reporting the side effect
on each day of the treatment period, but overall totals of participants reporting each side effect was not reported.
4Czapinski 1997 is an abstract only, so very little information is reported.
5Participants may have withdrawn due to adverse event alone or a combination of adverse events and poor efficacy (seizures).
A P P E N D I C E S
Appendix 1. Cochrane Epilepsy Group Specialized Register Search Strategy
#1 MeSH DESCRIPTOR Carbamazepine Explode All
#2 Carbamazepine OR Carbamezepine OR CBZ OR SPD417 OR Apo-Carbamazepine OR Atretol OR Biston OR Calepsin OR
Carbagen OR Carbamazepen OR Carbatrol OR Carbazepine OR Carbelan OR Epitol OR Equetro OR Finlepsin OR Karbamazepin
OR Lexin ORNeurotol ORNovo-Carbamaz OR Nu-Carbamazepine OR Sirtal OR Stazepin OR Stazepine OR Taro-Carbamazepine
OR Tegretal OR Tegretol OR Telesmin OR Teril OR Timonil
#3 #1 OR #2
#4 MeSH DESCRIPTOR Phenytoin Explode All
#5 Phenytoin ORDihydantoin ORDiphenylhydantoin ORDiphenylhydantoine ORDiphenylhydatanoin OR Fenitoina OR Pheny-
toine OR Phenytoinum OR Aleviatin OR Antisacer OR Auranile OR Causoin OR Citrullamon OR Citrulliamon OR Comital OR
Comitoina OR Convul ORDanten ORDantinal OR Dantoinal OR Dantoine ORDenyl ORDi-Hydan ORDi-Lan ORDi-Phetine
OR Didan OR Difenilhidantoina OR Difenin OR Difetoin OR Difhydan OR Dihycon OR Dilabid OR Dilantin OR Dilantine OR
Dillantin OR Dintoin OR Dintoina OR Diphantoin OR Diphedal OR Diphedan OR Diphenat OR Diphenin OR Diphenine OR
Dipheninum ORDiphentoin ORDiphentyn OR Diphenylan OR Ditoinate OR Ekko OR Elepsindon OR Enkelfel OR Epamin OR
Epanutin OR Epasmir OR Epdantoin OR Epdantoine OR Epelin OR Epifenyl OR Epihydan OR Epilan OR Epilantin OR Epinat
OR Epised OR Eptal OR Eptoin OR Fenantoin OR Fenidantoin OR Fentoin OR Fenylepsin OR Fenytoin OR Fenytoine OR Gerot-
epilan-D OR Hidan OR Hidantal OR Hidantilo OR Hidantina OR Hidantomin OR Hindatal OR Hydantal OR Hydantin OR
Hydantoin OR Hydantoinal OR Hydantol OR Ictalis OR Idantoil OR Idantoin OR Iphenylhydantoin OR Kessodanten OR Labopal
OR Lehydan OR Lepitoin OR Lepsin OR Mesantoin OR Minetoin OR Neos-Hidantoina OR Neosidantoina OR Novantoina OR
77Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Novophenytoin OR Om-hidantoina OR Om-Hydantoine OR Oxylan OR Phanantin OR Phanatine OR Phenatine OR Phenatoine
OR Phenhydan OR Phenhydanin OR Phenitoin OR Phentoin OR Phentytoin OR Phenytek OR Phenytex OR Ritmenal OR Saceril
OR Sanepil OR Silantin OR Sinergina OR Sodanthon OR Sodantoin OR Sodanton OR Solantin OR Solantoin OR Solantyl OR
Sylantoic OR Tacosal OR Thilophenyl OR TOIN OR Zentronal OR Zentropil OR PHT
#6 #4 OR #5
#7 ((adjunct* or ”add-on“ or ”add on“ or adjuvant* or combination* or polytherap*) not (monotherap* or alone or singl*)):TI
#8 (#3 AND #6 AND INREGISTER) NOT #7
#9 >16/09/2014:CRSCREATED
#10 #8 AND #9
Appendix 2. CENTRAL via CRSO search strategy
#1 MESH DESCRIPTOR Carbamazepine EXPLODE ALL TREES
#2 (biston OR carbamazepin* OR carbatrol OR cbz OR epitol OR equetro OR neurotop OR tegretol OR teril OR timonil):TI,AB,KY
#3 #1 OR #2
#4 MESH DESCRIPTOR Phenytoin EXPLODE ALL TREES
#5 (dilantin OR epanutin OR eptoin OR fenitoina OR phenytek OR phenytoin*):TI,AB,KY
#6 #4 OR #5
#7 (epilep* OR seizure* OR convuls*):TI,AB,KY
#8 MESH DESCRIPTOR Epilepsy EXPLODE ALL TREES
#9 MESH DESCRIPTOR Seizures EXPLODE ALL TREES
#10 #7 OR #8 OR #9
#11 eclampsia:TI
#12 #10 NOT #11
#13 #3 AND #6 AND #12
#14 ((adjunct* OR ”add-on“ OR ”add on“ OR adjuvant* OR combination* OR polytherap*) NOT (monotherap* or alone or singl*)):
TI
#15 #13 NOT #14
#16 (”Conference Abstract“):PT AND INEMBASE
#17 #15 NOT #16
#18 * NOT INMEDLINE AND 16/09/2014 TO 01/11/2016:CD
#19 #17 AND #18
Appendix 3. MEDLINE (Ovid) search strategy
The following search is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE
(Lefebvre 2011).
1. exp Carbamazepine/
2. (Carbamazepin$ or Carbamezepine or CBZ or SPD417 or Apo-Carbamazepine or Atretol or Biston or Calepsin or Carbagen or
Carbamazepen or Carbatrol or Carbazepine or Carbelan or Epitol or Equetro or Finlepsin or Karbamazepin or Lexin or Neurotol or
Novo-Carbamaz or Nu-Carbamazepine or Sirtal or Stazepin or Stazepine or Taro-Carbamazepine or Tegretal or Tegretol or Telesmin
or Teril or Timonil).tw.
3. 1 or 2
4. exp Phenytoin/
5. (Phenytoin$ or Dihydantoin or Diphenylhydantoin or Diphenylhydantoine or Diphenylhydatanoin or Fenitoina or Phenytoine or
Phenytoinum or Aleviatin or Antisacer or Auranile or Causoin or Citrullamon or Citrulliamon or Comital or Comitoina or Convul
or Danten or Dantinal or Dantoinal or Dantoine or Denyl or Di-Hydan or Di-Lan or Di-Phetine or Didan or Difenilhidantoina or
Difenin or Difetoin or Difhydan or Dihycon or Dilabid or Dilantin or Dilantine or Dillantin or Dintoin or Dintoina or Diphantoin
or Diphedal or Diphedan or Diphenat or Diphenin or Diphenine or Dipheninum or Diphentoin or Diphentyn or Diphenylan or
Ditoinate or Ekko or Elepsindon or Enkelfel or Epamin or Epanutin or Epasmir or Epdantoin or Epdantoine or Epelin or Epifenyl
or Epihydan or Epilan or Epilantin or Epinat or Epised or Eptal or Eptoin or Fenantoin or Fenidantoin or Fentoin or Fenylepsin or
Fenytoin or Fenytoine or Gerot-epilan-D or Hidan or Hidantal or Hidantilo or Hidantina or Hidantomin or Hindatal or Hydantal or
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Hydantin or Hydantoin or Hydantoinal or Hydantol or Ictalis or Idantoil or Idantoin or Iphenylhydantoin or Kessodanten or Labopal
or Lehydan or Lepitoin or Lepsin orMesantoin orMinetoin orNeos-Hidantoina or Neosidantoina or Novantoina or Novophenytoin or
Om-hidantoina or Om-Hydantoine or Oxylan or Phanantin or Phanatine or Phenatine or Phenatoine or Phenhydan or Phenhydanin
or Phenitoin or Phentoin or Phentytoin or Phenytek or Phenytex or Ritmenal or Saceril or Sanepil or Silantin or Sinergina or Sodanthon
or Sodantoin or Sodanton or Solantin or Solantoin or Solantyl or Sylantoic or Tacosal or Thilophenyl or TOIN or Zentronal or
Zentropil or PHT).tw.
6. 4 or 5
7. exp Epilepsy/
8. exp Seizures/
9. (epilep$ or seizure$ or convuls$).tw.
10. 7 or 8 or 9
11. exp Pre-Eclampsia/ or exp Eclampsia/
12. 10 not 11
13. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
14. clinical trials as topic.sh.
15. trial.ti.
16. 13 or 14 or 15
17. exp animals/ not humans.sh.
18. 16 not 17
19. 3 and 6 and 12 and 18
20. ((adjunct$ or ”add-on“ or ”add on“ or adjuvant$ or combination$ or polytherap$) not (monotherap$ or alone or singl$)).ti.
21. 19 not 20
22. remove duplicates from 21
23. limit 22 to ed=20140916-20161101
Appendix 4. SCOPUS Search Strategy
(((TITLE(carbamazepine OR carbamezepine OR cbz OR spd417 OR apo-carbamazepine OR atretol OR biston OR calepsin OR
carbagenORcarbamazepenORcarbatrolOR carbazepineOR carbelanOR epitolOR equetroORfinlepsinORkarbamazepinOR lexin
OR neurotol OR novo-carbamaz OR nu-carbamazepine OR sirtal OR stazepin OR stazepine OR taro-carbamazepine OR tegretal OR
tegretol OR telesmin OR teril OR timonil)) OR (ABS(carbamazepine OR carbamezepine OR cbz OR spd417 OR apo-carbamazepine
OR atretol OR biston OR calepsin OR carbagen OR carbamazepen OR carbatrol OR carbazepine OR carbelan OR epitol OR equetro
OR finlepsin OR karbamazepin OR lexinOR neurotol OR novo-carbamaz OR nu-carbamazepine OR sirtal OR stazepin OR stazepine
OR taro-carbamazepine OR tegretal OR tegretol OR telesmin OR teril OR timonil))) AND ((TITLE(phenytoin OR dihydantoin OR
diphenylhydantoin OR diphenylhydantoine OR diphenylhydatanoin OR fenitoina OR phenytoine OR phenytoinum OR aleviatin
OR antisacer OR auranile OR causoin OR citrullamon OR citrulliamon OR comital OR comitoina OR convul OR danten OR
dantinal OR dantoinal OR dantoine OR denyl OR di-hydan OR di-lan OR di-phetine OR didan OR difenilhidantoina OR difenin
OR difetoin OR difhydan OR dihycon OR dilabid OR dilantin OR dilantine OR dillantin OR dintoin OR dintoina OR diphantoin
OR diphedal OR diphedanOR diphenat OR diphenin OR diphenine OR dipheninumOR diphentoin OR diphentynOR diphenylan
OR ditoinate OR ekko OR elepsindon OR enkelfel OR epamin OR epanutin OR epasmir OR epdantoin OR epdantoine OR epelin
OR epifenyl OR epihydan OR epilan OR epilantin OR epinat OR epised OR eptal OR eptoin OR fenantoin OR fenidantoin
OR fentoin OR fenylepsin OR fenytoin OR fenytoine OR gerot-epilan-d OR hidan OR hidantal OR hidantilo OR hidantina OR
hidantomin OR hindatal OR hydantal OR hydantin OR hydantoin OR hydantoinal OR hydantol OR ictalis OR idantoil OR idantoin
OR iphenylhydantoin OR kessodanten OR labopal OR lehydan OR lepitoin OR lepsin OR mesantoin OR minetoin OR neos-
hidantoina OR neosidantoina OR novantoina OR novophenytoin OR om-hidantoina OR om-hydantoine OR oxylan OR phanantin
OR phanatine OR phenatine OR phenatoine OR phenhydan OR phenhydanin OR phenitoin OR phentoin OR phentytoin OR
phenytek OR phenytex OR ritmenal OR saceril OR sanepil OR silantin OR sinergina OR sodanthon OR sodantoin OR sodanton
OR solantin OR solantoin OR solantyl OR sylantoic OR tacosal OR thilophenyl OR toin OR zentronal OR zentropil OR pht))
OR (ABS(phenytoin OR dihydantoin OR diphenylhydantoin OR diphenylhydantoine OR diphenylhydatanoin OR fenitoina OR
phenytoine OR phenytoinum OR aleviatin OR antisacer OR auranile OR causoin OR citrullamon OR citrulliamon OR comital OR
comitoina OR convul OR danten OR dantinal OR dantoinal OR dantoine OR denyl OR di-hydan OR di-lan OR di-phetine OR
didan OR difenilhidantoina OR difenin OR difetoin OR difhydan OR dihycon OR dilabid OR dilantin OR dilantine OR dillantin
79Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
OR dintoin OR dintoina OR diphantoin OR diphedal OR diphedan OR diphenat OR diphenin OR diphenine OR dipheninum
OR diphentoin OR diphentyn OR diphenylan OR ditoinate OR ekko OR elepsindon OR enkelfel OR epamin OR epanutin OR
epasmir OR epdantoin OR epdantoine OR epelin OR epifenyl OR epihydan OR epilan OR epilantin OR epinat OR epised OR
eptal OR eptoin OR fenantoin OR fenidantoin OR fentoin OR fenylepsin OR fenytoin OR fenytoine OR gerot-epilan-d OR hidan
OR hidantal OR hidantilo OR hidantina OR hidantomin OR hindatal OR hydantal OR hydantin OR hydantoin OR hydantoinal
OR hydantol OR ictalis OR idantoil OR idantoin OR iphenylhydantoin OR kessodanten OR labopal OR lehydan OR lepitoin OR
lepsin OR mesantoin OR minetoin OR neos-hidantoina OR neosidantoina OR novantoina OR novophenytoin OR om-hidantoina
OR om-hydantoine OR oxylan OR phanantin OR phanatine OR phenatine OR phenatoine OR phenhydan OR phenhydanin OR
phenitoin OR phentoin OR phentytoin OR phenytek OR phenytex OR ritmenal OR saceril OR sanepil OR silantin OR sinergina
OR sodanthon OR sodantoin OR sodanton OR solantin OR solantoin OR solantyl OR sylantoic OR tacosal OR thilophenyl OR
toin OR zentronal OR zentropil OR pht))) AND ((TITLE-ABS-KEY(epilep* OR ”infantile spasm“ OR seizure OR convuls* OR
(syndrome W/2 (aicardi OR angelman OR doose OR dravet OR janz OR jeavons OR ”landau kleffner“ OR ”lennox gastaut“ OR
ohtahara OR panayiotopoulos OR rasmussen OR rett OR ”sturge weber“ OR tassinari OR ”unverricht lundborg“ OR west)) OR ”ring
chromosome 20“ OR ”R20“ OR ”myoclonic encephalopathy“ OR ”pyridoxine dependency“) AND NOT (TITLE(*eclampsia) OR
INDEXTERMS(*eclampsia))) OR (TITLE-ABS-KEY(lafora* W/4 (disease OR epilep*)) AND NOT (TITLE(dog OR canine) OR
INDEXTERMS(dog OR canine)))) AND (TITLE((randomiz* OR randomis* OR controlled OR placebo OR blind* OR unblind*
OR ”parallel group“ OR crossover OR ”cross over“ OR cluster OR ”head to head“) PRE/2 (trial OR method OR procedure OR
study)) OR ABS((randomiz* OR randomis* OR controlled OR placebo OR blind* OR unblind* OR ”parallel group“ OR crossover
OR ”cross over“ OR cluster OR ”head to head“) PRE/2 (trial OR method OR procedure OR study)))) ANDNOT (TITLE((adjunct*
OR ”add-on“ OR ”add on“ OR adjuvant* OR combination* OR polytherap*) AND NOT (monotherap* OR alone OR singl*)))
WH A T ’ S N E W
Last assessed as up-to-date: 1 November 2016.
Date Event Description
1 November 2016 New search has been performed Searches updated 1November 2016; nonew trials iden-
tified
1 November 2016 New citation required but conclusions have not
changed
Conclusions are unchanged
H I S T O R Y
Protocol first published: Issue 1, 2000
Review first published: Issue 2, 2002
Date Event Description
16 September 2014 New search has been performed Searches updated 16th September 2014
16 September 2014 New citation required but conclusions have not
changed
Three new studies included; conclusions remain the
same
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(Continued)
1 November 2010 New search has been performed Searches updated 1st November 2009; no new trials
identified
12 August 2009 Amended Copyedits made at editorial base
23 September 2008 Amended Converted to new review format
26 September 2007 New search has been performed Searches updated 27th July 2007; no new trials iden-
tified
C O N T R I B U T I O N S O F A U T H O R S
SJ Nolan assessed studies for inclusion in the review update, assessed risk of bias in all included studies, performed analyses in SAS
version 9.2, Stata version 11.2 and Meta view, added survival plots and ’Summary of findings’ tables and updated the text of the review
under the supervision of C Tudur Smith and AG Marson.
C Tudur Smith was the lead author of the original review, assessed eligibility and methodological quality of original individual studies,
organised and cleaned the IPD sets, performed data validation checks and statistical analyses, and co-wrote the original review.
AG Marson obtained IPD from trial investigators, provided guidance with the clinical interpretation of results, assessed eligibility and
methodological quality of individual studies and co-wrote the original review.
J Weston independently assessed risk of bias in all included studies.
D E C L A R A T I O N S O F I N T E R E S T
Sarah J Nevitt: none known
Anthony G Marson: A consortium of pharmaceutical companies (GSK, EISAI, UCB Pharma) funded the National Audit of Seizure
Management in Hospitals (NASH) through grants paid to University of Liverpool. Professor Tony Marson is Theme Leader for
Managing Complex Needs at NIHR CLAHRC NWC.
Jennifer Weston: none known
Catrin Tudur Smith: none known
S O U R C E S O F S U P P O R T
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Internal sources
• NHS Research & Development Programme, UK.
External sources
• Medical Research Council, UK.
• National Institute for Health Research (NIHR), UK.
This review update was supported by the National Institute for Health Research, via Cochrane Infrastructure Grant funding to the
Epilepsy Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the
Systematic Reviews Programme, NIHR, NHS or the Department of Health.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
December 2014: title was changed to specify that the review uses individual participant data (IPD).
Sensitivity analyses added, following identification of potential misclassification of seizure type. The existence of misclassification in
the individual studies could not have been known at the time of writing the original protocol.
Addition of the outcome ’Time to six-month remission’ for consistency with the other reviews in the series of Cochrane IPD reviews
investigating pairwise monotherapy comparisons.
N O T E S
Sarah J Nolan (lead author of 2015 update) is now Sarah J Nevitt
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants [adverse effects; ∗therapeutic use]; Carbamazepine [adverse effects; ∗therapeutic use]; Epilepsies, Partial [∗drug therapy];
Epilepsy,Generalized [∗drug therapy]; Induction Chemotherapy; Phenytoin [adverse effects; ∗therapeutic use]; Randomized Controlled
Trials as Topic; Withholding Treatment
MeSH check words
Adult; Child; Humans
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